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Swelling-activated Cl- current (ICl,swell) is an outwardly rectifying Cl- current that 
influences cardiac electric activities and acts as a potential effector of mechanoelectrical 
feedback that antagonizes the effects of stretch-activated cation channels. Persistent 
activation of ICl,swell has been observed in multiple models of cardiovascular diseases. 
Previously we showed that angiotensin II (AngII) signaling and reactive oxygen species 
(ROS) produced by NADPH oxidase (NOX) are involved in the activation of ICl, swell by 
both 1-integrin stretch and osmotic swelling. Because endothelin-1 (ET-1) is a potential 
downstream mediator of AngII and ETA receptor blockade abrogates AngII-induced ROS 
generation, we studied how ET-1 signaling regulates ICl,swell and the relationship between 
xv 
 
 
AngII and ET-1 signaling. Under isosmotic conditions, ET-1 elicited an outwardly 
rectifying Cl- current that was fully blocked by the highly selective ICl,swell inhibitor 
DCPIB and by osmotic shrinkage. Selective ETA blockade (BQ123), but not ETB 
blockade (BQ788), fully suppressed the ET-1-induced current. ET-1-induced ICl,swell was 
abolished by blockade of EGFR kinase (AG1478) and PI-3K inhibitors (LY294002 and 
wortmannin), which also suppress 1-integrin stretch- and swelling-induced ICl,swell.  
ET-1-induced ICl,swell was abrogated by ebselen, a membrane-permeant 
glutathione peroxidase mimetic that dismutates H2O2 to H2O, suggesting that ROS were 
required intermediates in ET-1-induced activation of ICl,swell. Both NOX and mitochondria 
are important sources of ROS in cardiomyocytes. Blocking NOX with apocynin or 
mitochondrial complex I with rotenone both completely suppressed ET-1-induced ROS 
generation and activation of ICl,swell, indicating that ROS from both NOX and 
mitochondria were required to activate ICl,swell, and complete block by inhibitors of either 
ROS source suggests mitochondrial and NOX must act in series rather than in parallel. 
ICl,swell elicited by antimycin A, which stimulates superoxide production by 
mitochondrial complex III, was insensitive to NOX inhibitor apocynin and the NOX 
fusion peptide inhibitor gp91ds-tat. Activation of ICl,swell induced by diazoxide, which 
stimulates mitochondrial ROS production by opening mitochondrial KATP channels, was 
not affected by gp91ds-tat. These data suggests that mitochondrial ROS is downstream 
from NOX in the regulation of ICl,swell. Mitochondrial ROS production that is enhanced by 
NOX ROS is likely to be responsible for the activation of ICl,swell by ET-1.  
xvi 
 
 
In order to determine the role of ERK in the proposed signaling pathway that 
regulates ICl,swell, we examined the effect of ERK inhibitors (PD 98059 and U0216) on the 
activation of ICl,swell  elicited by ET-1, EGF, and H2O2. ERK inhibitors partially blocked 
ET-1-induced ICl,swell but fully inhibited activation of ICl,swell in response to EGF. 
However, ERK inhibitors did not affect ICl,swell elicited by exogenous H2O2.   
We also established the the relationship of ET-1 to AngII and osmotic swelling in 
the regulation of ET-1 ICl,swell. ETA blockade abolished ICl,swell elicited by both AngII and 
osmotic swelling, whereas AT1 blockade did not effect ET-1-induced ICl,swell, suggesting 
that ET-1 signaling is downstream from AngII and osmotic swelling.  
HL-1 cell is a murine atrial cell line that retain phenotypic characteristics of adult 
cardiomyocytes. We showed that osmotic swelling and ET-1 turned on DCPIB-sensitive 
outwardly rectifying Cl- current in HL-1 cells with both physiological and symmetrical 
Cl- gradients. The swelling-induced current was suppressed by gp91ds-tat and rotenone 
but insensitive to apocynin. Blockade of ETA receptor (BQ123) and NOX (gp91ds-tat) 
completely inhibited ET-1-induced ICl,swell in HL-1 cells. These data indicate that ICl,swell 
is present in HL-1 cell and regulated by similar mechanisms as in native cells.  
 Finally, we confirmed the production of ROS by ET-1 signaling by flow 
cytometry of HL-1 cells using the nominally H2O2-selective fluorescent probe 
C-H2DCFDA-AM.  Exposure to ET-1 increased ROS production, as did H2O2, a positive 
control.  ET-1-induced ROS production was fully suppressed by both gp91ds-tat and 
rotenone.  HL-1 cell ROS production also was stimulated by the mitochondrial complex 
xvii 
 
 
III inhibitor antimycin A, and antimycin A-induced ROS production was blocked by 
rotenone but not by gp91ds-tat. 
 These data suggest that ET-1 ETA receptor signaling elicits ICl,swell by sequentially 
stimulating ROS production by NOX and mitochondria.  ETA receptor signaling is down 
stream from AngII in the osmotic swelling-induced activation of ICl,swell and is upstream 
from EGFR kinase and PI-3K.  Endothelin signaling is likely to be an important means of 
activating ROS production and ICl,swell in a variety of cardiovascular diseases.  
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Chapter 1 
INTRODUCTION 
 
 
Endothelins (ETs) are a family of 21-amino-acid peptides that consists of three 
identified members: ET-1, ET-2 and ET-3. ET-1 is the isoform predominantly 
responsible for cardiovascular effects (Kedzierski & Yanagisawa, 2001). ET-1 plays a 
critical role in the regulation of physiological cardiovascular function, but excessive 
levels of ET-1 have been linked to various cardiovascular pathologies. 
ET-1 interacts with two G protein coupled receptor (GPCR) subtypes, ETA and 
ETB, which are widely and heterogeneously distributed throughout the heart (Russell & 
Molenaar, 2000). Recently reactive oxygen species (ROS) have been identified as crucial 
mediators in ET-1 signaling. ET-1-induced ROS generation plays an important role in 
certain physiological and pathophysiological effects, and is well positioned to be a 
potential regulator of redox sensitive ion channels and transporters, among which is the 
swelling-activated Cl- current (ICl,swell). 
 ICl,swell is a cell volume and mechanosensitive anion current that has profound 
implications in cellular volume regulation, apoptosis, and cardiac electrical activity (for 
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review, see Baumgarten & Clemo, 2003). Persistent activation of ICl,swell has been 
observed in multiple cardiovascular disease models (Clemo et al., 1998; Clemo et al., 
1999b; Clemo et al., 2000; Clemo et al., 2001; Patel et al., 2003).  Previously we have 
shown that angiotensin II (AngII) signaling and ROS produced by NADPH oxidase 
(NOX) are responsible for the activation of ICl,swell by both 1-integrin stretch and 
osmotic swelling (Browe & Baumgarten, 2004; Browe & Baumgarten, 2006; Ren et al., 
2008). Besides NOX, another important source of ROS in cardiomyocytes is 
mitochondria, and we have shown that mitochondrial ROS is also involved in the 
regulation of ICl,swell (Browe & Baumgarten, 2007; Deng et al., 2009; Raucci, Jr. & 
Baumgarten, 2009). The localization of NOX in the sarcolemmal membrane and the high 
density of subsarcolemmal mitochondria in cardiomyocytes raise the feasibility of their 
crosstalk, and crosstalk between NOX and mitochondria has emerged as a new concept of 
cellular signaling (Kimura et al., 2005a; Kimura et al., 2005b; Caldiz et al., 2007).   
The synthesis and release of ET-1 can be induced by AngII, and accumulating 
evidence indicates that ET-1 might act as a downstream mediator of AngII in multiple 
physiological and pathophysiological processes including ROS production and 
arrhythmogenic effects. It has been reported that ET-1 is a potential modulator of ICl,swell 
(Du & Sorota, 2000) and anion efflux (Tilly et al., 1996a) in cardiac myocytes. However, 
the downstream signaling pathways and the relationship between AngII and ET-1 
signaling in the regulation of ICl,swell remain unknown.   
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1.1. ET-1 in Cardiac Physiology and Pathology   
ET-1 was first identified in 1988 as a vasoconstrictor peptide produced by 
vascular endothelial cells (Yanagisawa et al., 1988). ET-1 is also produced by other cell 
types including leukocytes (Sessa et al., 1991), macrophages (Ehrenreich et al., 1990), 
smooth muscle cells (Hahn et al., 1990), and cardiomyocytes (Ito et al., 1993). Vascular 
endothelial cells secrete ET-1 preferentially towards the abluminal side, i.e. smooth 
muscle side, rather than the luminal side (Yoshimoto et al., 1991; Wagner et al., 1992). 
Under physiological conditions, the plasma concentration of ET-1 is lower than the 
pharmacological threshold. Therefore, ET-1 is generally regarded as an 
autocrine/paracrine factor rather than a circulating hormone.  
Physiologically, ET-1 is essential for embryonic development of cardiovascular 
system, and endogenously generated ET-1 plays an important role in maintenance of 
vascular tone and blood pressure (Haynes & Webb, 1994; Veniant et al., 1994). ET-1 
elicits a positive inotropic effect in cardiac muscle of most species investigated, and the 
extent of the positive inotropic effect of ET-1 on human heart appears to be chamber-
specific and depends on the pathological state of the heart (Moravec et al., 1989; Endoh 
& Takanashi, 1991; Wang et al., 1991; Kasai et al., 1994; Dhein et al., 2000; Nagasaka et 
al., 2003; Mollmann et al., 2007). The positive inotropic effect of ET-1 recently has been 
largely attributed to intracellular ROS production and ROS- mediated stimulation of 
Na+/H+ exchanger 1 (NHE1) (Cingolani et al., 2006; Cingolani & Ennis, 2007; De Giusti 
et al., 2008). ET-1 is also implicated in the slow  phase of stretch-induced inotropic 
response, which involves a sequential Ang II – ET release and subsequent increase of 
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Ca2+ entry (Cingolani et al., 2001; Cingolani et al., 2003; Ennis et al., 2005; Cingolani et 
al., 2005). It is widely accepted that the inotropic effect of ET-1 is mediated by ETA 
receptors (Ishikawa et al., 1988; Kelso et al., 2000), whereas the role of ETB receptor is 
contentious (Leite-Moreira & Bras-Silva, 2004).  
The ET system is over-activated in multiple cardiovascular disorders including 
congestive heart failure (Moe et al., 2003), atrial fibrillation (Tuinenburg et al., 1998; 
Brundel et al., 2001; Masson et al., 2006), essential hypertension (Touyz & Schiffrin, 
2003), salt sensitive hypertension (Feldstein & Romero, 2007), pulmonary hypertension 
(Jasmin et al., 2003), pre-eclampsia (Florijn et al., 1991), atherosclerosis (Bousette & 
Giaid, 2003), stable coronary artery disease (Pernow, 2004), acute myocardial infarction 
(Cernacek et al., 2003), ischemia/reperfusion injury (Pernow & Wang, 1997), 
myocarditis (Ono et al., 1999), sepsis induced myocardial dysfunction (Chopra & 
Sharma, 2007), and diabetic cardiovascular complications (Chakrabarti et al., 2002). 
Furthermore, ET-1 participates in the structural remodeling of heart as a potent mitogenic 
(Shubeita et al., 1990; Ito et al., 1991), pro-fibrotic (Teder & Noble, 2000; Clozel & 
Salloukh, 2005), and pro-inflammatory factor (Hayasaki et al., 1996; Yang et al., 2004).  
1.2. The Effect ET-1 on Cardiac Electrical Activity and Ion Channels 
1.2.1. Sinoatrial Node (SAN)  
In isolated rabbit SAN preparations, ET-1 exhibits a negative chronotropic effect 
via ETA receptors, which reflects prolongation of action potential duration (APD), a 
positive shift of take-off potential, and a decrease in the slope of the pacemaker potential. 
5 
 
 
This negative chronotropic effect was ascribed to the effects of ET-1 on various currents: 
inhibition of the L-type Ca2+ current (ICa,L ), the T-type Ca2+ current (ICa,T), the 
hyperpolarization- activated inward current (If), and an increase of background K+ current 
(Tanaka et al., 1997; Tanaka et al., 1998; Ono et al., 2001). Modulation of Cl channels 
apparently was not considered. However, the effects of ET-1 on SAN may differ between 
species. Under exactly the same experimental conditions, ET-1 exerted a positive 
chronotropic effect on guinea-pig SAN (Ono et al., 2001). 
1.2.2. Atria   
APD in cardiomyocytes is largely governed by the amplitude and kinetics of ICa,L, 
rapid delayed rectifier K+ current (IKr) and slow delayed rectifier K+ current (IKs). Atria 
has intrinsically shorter APD than that of ventricle, a difference that is partially due to 
atrial-specific expression of the ultra-rapid delayed rectifier K+ current (IKur) and atrial-
predominant expression of the muscarinic K+ current (IK-ACh) (Schram et al., 2002). ET-1 
hyperpolarizes the membrane and shortens the APD of guinea-pig and canine atrial 
myocytes (Yorikane et al., 1991; Ono et al., 1994). A recent study showed that ET-1 had 
no effect on the basal APD of human atrial cells but completely abolished the APD 
prolongation induced by isoproterenol (Redpath et al., 2006). As in SAN, the ionic basis 
for the atrial APD shortening effect of ET-1 appears to vary between species. In guinea-
pig atria, ET-1 dose dependently inhibits ICa,L and activates IK-ACh by stimulating a 
pertussis toxin-sensitive GTP-binding protein via ETA receptor (Ono et al., 1994). The 
same group also demonstrated that ET-1 augments IKs in guinea-pig atrial myocytes 
(Ono, 2003). However, ET-1 was shown to inhibit IK-ACh in rabbit and mouse atrial 
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myocytes (Spiers et al., 1996; Cho et al., 2005). ET-1 either reduces (Cheng et al., 1995) 
or has no effect on basal ICa,L (Redpath et al., 2006) of human atrial cells, and dual 
effects, depending on the ICa,L density before ET-1 treatment, were also reported (Boixel 
et al., 2001). Besides Ca2+ and K+ currents, ET-1 activates ICl,swell in canine atrial 
myocytes (Du & Sorota, 2000). As an outwardly rectifying current that reverses near the 
Cl- equilibrium potential (ECl), activation of ICl,swell shortens APD (Hiraoka et al., 1998). 
Another current that may contribute to shortening of APD is the Na+/Ca2+ exchanger 
(NCX)-generated current (INaCa) (Janvier et al., 1997). ET-1 activates NHE1 and increase 
[Na]i, which promotes NCX in reverse mode (Cingolani et al., 2001; Cingolani & Ennis, 
2007). With a stoichiometry of 3Na+:1Ca2+, electrogenic NCX will generate a 
repolarizing outward current when operating in the reverse mode.  
Besides the ion channels that have direct effects on APD, ET-1 also modulates 
other channels in atria. A recent study showed that ET-1 inhibits human atrial inward 
rectifier K+ current (IK1) via ETA receptors and a protein kinase C (PKC)-mediated 
pathway (Kiesecker et al. , 2006). Potentially important for the present study, ET-1 
inhibits the cAMP-activated Cl− current (ICl,cAMP), which results from CFTR (cystic 
fibrosis transmembrane conductance regulator), via ETA receptors in human atrial 
myocytes (Tsai et a l., 2001). ET-1 also activates phosphatidylinositol 3′, 4′, 5′-
trisphosphate receptors (IP3R), which potentially plays a role in atrial excitation-
contraction (E-C) coupling and contributes to arrhythmogenic spontaneous diastolic Ca2+ 
transients (Lipp et al. , 2000; Mackenzie et a l., 2002; Zima & Blatter, 2004; Li et al. , 
2005). The effects of ET-1 on atrial Na+ channels seem controversial. A stimulatory 
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effect was observed by Cheng et al. (1995), whereas ET-1 failed to significantly alter the 
maximum upstroke velocity, Vmax, of the action potential, which is an indicator of the 
size of INa (Geller et al., 2000; Magyar et al., 2000). 
1.2.3. Ventricles    
 Most studies have shown that ET-1 prolongs APD in His bundle and ventricular 
myocardium (Szokodi et al., 1998; Geller et al., 1998a; Geller et al., 1998b; Merkely et 
al., 2002). APD in ventricular myocytes largely is determined by the amplitude and the 
kinetics of ICa,L, IKr and IKs. The effect of ET-1 on ventricular ICa,L is highly controversial: 
an increase (Lauer et al., 1992; Kelso et al., 1998; Woo & Lee, 1999; He et al., 2000), 
decrease (Tohse et al., 1990; Magyar et al., 2000), no change (Thomas et al., 1997; 
Watanabe & Endoh, 2000), or dual effects (Watanabe & Endoh, 1999) were all reported. 
The effects of ET-1 on ventricular K+ channel appears to vary between the species, but 
overall, ET-1 exerts an inhibitory effect on K+ channels. ET-1 was shown to inhibit the 
IKs and partially inhibit IK-ACh in guinea pig ventricles (Kobayashi et al., 1996; Washizuka 
et al., 1997). In human ventricular myocytes, ET-1 inhibits IKr (Magyar et al., 2000). In 
rat ventricular myocytes, however, the predominant effects of ET-1 is to inhibit a non-
inactivating steady-state background K+ current (Iss) (James et al., 2001). Interestingly, 
ET-1 was reported to augment IKs in guinea pig atrial myocytes, where it shorten APD 
(Ono, 2003), but inhibit IKs in guinea pig ventricular myocytes, where it prolongs APD 
(Washizuka et al., 1997). The reason for the apparently differential effects is not known.  
Previous studies have indicated that ET-1 regulates reappearance of T-type Ca2+ 
channel (ICa,T) in failing hearts both in vivo and in vitro (Izumi et al., 2003).Reappearance 
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of ICa,T in hypertrophic and failing heart has been associated with Ca2+ overload, triggered 
activity, and Ca2+-dependent signaling that mediates cell apoptosis (Nuss & Houser, 
1993; Martinez et al., 1999; Levine et al., 2000). Moreover, ET-1 induces spontaneous 
Ca2+ transients and triggered activity in ventricular myocytes that are attributed to 
activation of IP3R (Proven et al., 2006).  
1.3. ET-1 and Cardiac Arrhythmias  
The majority of arrhythmias are attributed to three mechanisms: reentry, increased 
automaticity, and triggered activity. ET-1 not only induces or exacerbates ischemia-
induced ventricular arrhythmias (Ezra et al., 1989; Salvati et al., 1991; Polontchouk et 
al., 2001), it also has a direct arrhythmogenic action that is not solely attributable to 
myocardial ischemia (Yorikane & Koike, 1990; Yorikane et al., 1990; Szabo et al., 
2000). It has been indicated that prolongation of APD and generation of early 
afterdepolarization (EAD) are involved in the genesis of ET-1-induced ventricular 
arrhythmias (Szokodi et al., 1998; Geller et al., 1998a; Geller et al., 1998b; Merkely et 
al., 2000; Merkely et al., 2002). Reintroduction of ICa,T in ventricles and activation IP3R 
may contribute to ET-1-induced triggered activity (Levine et al., 2000; Proven et al., 
2006). Moreover, ET-1 also causes regional heterogeneity and increase of action 
potential (AP) dispersion, which may favor a reentry mechanism (Geller et al., 1998a).  
Although the arrhythmogenic effects of ET-1 were first identified in ventricles, 
ET-1 may participate in the genesis of atrial arrhythmias as well. It has been reported that 
plasma and tissue ET-1 are elevated in patients with atrial fibrillation (Tuinenburg et al., 
1998; Brundel et al., 2001; Masson et al., 2006), and ET-1 was shown to induce 
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arrhythmic contractions in human right atrial tissues (Burrell et al., 2000). The 
pathophysiological basis underlying the arrhythmogenic effects of ET-1 on atria have not 
been fully understood. Nevertheless, shortening of effective refractory period (ERP), 
which is a consequence of APD abbreviation, is an important electrophysiological 
substrate that facilitates reentrant arrhythmias including atrial fibrillation (Shiroshita-
Takeshita et al., 2005). In addition, activation of IP3R by ET-1 is a potential mechanism 
for arrhythmogenic Ca2+ sparks and triggered activity in atria (Zima & Blatter, 2004; Li 
et al., 2005). ET-1 is also known to induce oxidative stress and inflammation, which have 
a considerable impact on the energetic, electrophysiological and mechanical properties of 
atria contributing to atrial remodeling and fibrillation (Carnes et al., 2001; 
Korantzopoulos et al., 2004; Engelmann & Svendsen, 2005; Korantzopoulos et al., 2005; 
Goldstein & Stambler, 2005; Kim et al., 2005; Dudley, Jr. et al., 2005; Wolin & Gupte, 
2005; Boos et al., 2006).  
1.4. ET-1-Induced Signaling  
Both ETA and ETB receptor couple to the Gq family of heterotrimeric G proteins, 
and there is some evidence that they also couple to Gi/o (Hilal-Dandan et al., 1992; Hilal-
Dandan et al., 1994; Hilal-Dandan et al., 1997). The best characterized ET-1 signaling 
pathway in cardiomyocyte are the diacylglycerol (DAG)/PKC cascades, the mitogen-
activated protein kinase (MAPK) cascades, and the phosphoinositide -3 kinase (PI-3K)-
dependent cascades. Recently, ROS signaling and epidermal growth factor receptor 
(EGFR)-mediated pathway also were identified.  
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1.4.1. DAG/PKC Signaling Cascades 
ET-1 binding to ETA receptor stimulates exchange of GDP for GTP on Gαq and 
the heterotrimeric G protein dissociates into Gαq and βγ dimmers. Both Gαq and βγ 
dimers are able to activate phospholipase Cβ (PLCβ) (Rhee, 2001; Fukami, 2002). 
Following activation, PLCβ hydrolyzes the membrane phospholipid, phosphatidylinositol 
4′, 5′-bisphosphate [PtdIns (4, 5)P2] to DAG and inositol 1′, 4′, 5′-trisphosphate [Ins(1, 4, 
5)P3]. DAG is a physiological regulator of several PKC isoforms that translocate from the 
cytoplasm to the membrane fraction. Conventional PKC-α (cPKCα), novel PKC- δ 
(nPKCδ) and novel PKC-ε (nPKCε) are involved  in ET-1 induced cellar response (Clerk 
& Sugden, 1997a; Clerk & Sugden, 1999; Zolk et al., 2004; Wolf et al., 2004; Takeishi et 
al., 2007). Moreover, PKC modulate multiple signaling pathways including MAPK and  
PI-3K cascade(Gomez et al., 1996; Chiloeches et al., 1999).  
1.4.2. MAPK Cascades  
Three MAPK cascades have been well characterized in the cardiomyocytes: the 
extracellular signal-regulated kinase (ERK) cascade, the c-jun N terminal kinase (JNK) 
cascade, and the P38-MAPK cascade. ERK1 and ERK2 are robustly activated by ET-1 in 
cardiac myocytes (Bogoyevitch et al., 1993; Bogoyevitch et al., 1994). The upstream of 
ERK1/2 are Raf (A-Raf, B-Raf, and c-Raf) and mitogen-activated protein kinase kinase 
(MEK1/MEK2). Several lines of evidence shows that the small G protein Ras is involved 
in Raf activation in cardiomyocytes (Avruch et al., 2001; Muslin, 2005), and PKC was 
shown to activate Ras in cardiac myocytes (Chiloeches et al., 1999). Another possible 
pathway for Ras activation is EGFR-mediated signaling, which results in the activation of 
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Sos, a guanine-nucleotide exchange factor (GEF) for Ras (Smith et al., 2004; Chan et al., 
2006). Moreover, ET-1-induced ROS may also be involved in the activation of ERK1/2 
because ERK signaling cascade has been shown to be redox sensitive (McCubrey et al., 
2006). 
ET-1 also evidently activates the JNK and p38-MAPK cascades in cardiac 
myocytes (Clerk & Sugden, 1997b; Clerk et al., 1998), but the upstream modulators have 
not been clearly defined. The involvement of nPKC-ε (Bayer et al., 2003), Rac (Clerk et 
al., 2001; Clerk et al., 2002), ERK1/2 (Clerk et al., 2002), and ROS (Sugden & Clerk, 
2006) have been suggested.  
1.4.3. PI-3K-Dependent Cascades  
ET-1 activates the PI-3K/Akt pathway, although the activation is relatively weak 
in comparison to other agonists (Pham et al., 2001; Sugden, 2002). The PI-3K group of 
lipid kinases catalyze the formation of PtdIns(3, 4, 5)P3 from PtdIns(4, 5)P2. PtdIns(3, 4, 
5)P3 remains in the membrane where it activates PtdIns(3, 4, 5)P3-dependent kinase 
(PDK), which in turn phosphorylate and activate Akt (Katso et al., 2001).  
  Possible upstream activators of PI-3K signaling include receptor protein tyrosine 
kinase (PTK) and βγ dimmers of heterotrimeric G-proteins (Hoyal et al., 2003; Heineke 
& Molkentin, 2006).  
1.4.4. EGFR- Mediated Pathway  
It has been demonstrated that ET-1 induces EGFR transactivation in cardiac 
myocytes, and this receptor transactivtion pathway is crucial for hypertrophy response 
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induced by ET-1 and other GPCR agonist such as AngII (Pierce et al., 2001; Asakura et 
al., 2002; Kodama et al., 2002). The transactivation process involves activation of matrix 
metalloproteinases (MMP), which cleavages and allows shedding of extracellular surface 
heparin-binding EGF (Prenzel et al., 1999; Anderson et al., 2004). Upon EGF binding, 
EGFR kinase dimerizes, trans-autophosphorylates six specific tyrosine residues within its 
cytoplasmic tail, and then EGFR kinase is able to recruit and phosphorylate various 
adaptor and signaling molecules (Shah, 2002).   
In heart, EGFR kinase is coupled to PI-3K (Oudit et al., 2004; Shah et al., 2006). 
Both PI-3K and EGFR kinase were shown to be involved in NOX activation (Seshiah et 
al., 2002; Shah & Catt, 2003; Shah & Catt, 2004). 
1.4.5. ROS Signaling 
An increasing body of evidence indicates that ROS are important second 
messengers that participate in multiple signaling pathways. ROS, such as H2O2 and O2−, 
can modify cysteine residues, heme groups, and iron-sulfur centers of signaling 
molecules, which may have a profound impact on the signaling pathways (Demple et al., 
1999; Salmeen & Barford, 2005). The principal growth-promoting signaling pathways in 
cardiomyocytes, including ERK, JNK, P38 MAPK, and PI3K/Akt pathways, all are redox 
sensitive (for review, see Takimoto & Kass, 2007).  
ET-1 induces ROS generation in cardiomyocyte, and ROS mediate the inotropic 
response to ET-1 (Cingolani et al., 2006; De, V et al., 2008; De Giusti et al., 2008) as 
well as multiple pathways associated with ET-1-induced cardiac hypertrophy (Cheng et 
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al., 1999; Tanaka et al., 2001; Cheng et al., 2005). In addition to redox-sensitive 
signaling molecules, ROS can modulate functions of ion channels and transporters, which 
may have profound impact on cardiac electric activities as well as other functions (for 
review, see Zima & Blatter, 2006).  
1.4.6. Non-receptor PTKs and Other Signaling Pathways  
The non-receptor PTKs present in cardiomyocytes including the Src family and 
the family consisting of focal adhesion kinase (FAK) and Pro-rich Tyr-kinase 2 (PYK2). 
ET-1 activates Src (Kovacic et al., 1998) and focal adhesion associated pathways that 
involves FAK, PYK2, and p130Cas (Eble et al., 2000). ET-1 also activates RhoA and 
Rac1, which are members of Rho family (Clerk et al., 2001). Moreover, ET-1 activates 
calcium/calcineurin pathways by modulating intracellular Ca2+ concentration and IP3-
induced Ca2+ release (Kakita et al., 2001; Iwai-Kanai & Hasegawa, 2004; Higazi et al., 
2009) 
1.5. ET-1 as a Potential Downstream Mediator of AngII  
Ang II induces preproET-1(ppET-1) gene expression in multiple cell types 
including cardiomyocytes (Ito et al., 1993). The induction of ppET-1 gene was attributed 
to AngII receptor type 1 (AT1R)  and a PKC-dependent pathway (Sung et al., 1994), and 
the AP-1 binding sites in ppET-1 promoter is crucial (Imai et al., 1992; Hong et al., 
2004). Besides transcriptional regulation, AngII also can trigger the release of preformed 
ET-1, which involves degranulation of ET-1-containing storage granules on the cell 
surface (Villa-Abrille et al., 2006). 
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 Accumulating evidence indicates that ET-1 acts as a downstream mediator of 
AngII in multiple AngII-induced effects, including hemodynamic response, ROS 
production, inotropic effect, mitogenic effect, fibrosis, inflammation, and 
arrhythmogenisis.  In vivo studies demonstrated that pretreatment with the nonselective 
ET receptor antagonist bosentan blunted the increase in blood pressure, the decrease in 
cardiac output, and the decrease in total peripheral conductance induced by acute Ang II 
infusion both in normotensive and spontaneously hypertensive rats (SHR) (Balakrishnan 
et al., 1996). Chronic infusion of Ang II to Sprague-Dawley rats markedly enhanced ET-
1 levels in vascular tissues and plasma, and ETA-selective antagonist pretreatment 
abolished the rise in blood pressure as wells as AngII-induced vascular hyper-
responsiveness to a variety of vasoconstrictors (Rajagopalan et al., 1997). In healthy 
human subjects, ETA-selective antagonist BQ123 substantially attenuated both systemic 
and renal hemodynamic effects of low-dose AngII infusion (Montanari et al., 2003). The 
role of ET-1 in AngII-evoked hemodynamic response was also verified in transgenic 
animals. In transgenic hypertensive mice overexpressing both human renin and 
angiotensinogen genes (dTGR), expression of ET-1 was robustly enhanced in cardiac and 
vascular  tissues, and ET receptor antagonist significantly lowered blood pressure (Maki 
et al., 1998; Maki et al., 2004).  
 There is some evidence indicates that ET-1 mediates AngII-induce ROS 
production in both vascular smooth muscle cells (VSMCs) and cardiomyocytes. In 
VSMCs, AngII elicits superoxide production in a bimodal fashion: a first peak within 10-
15 min after treatment followed by a second peak after 4-6 h (Laplante et al., 2005). 
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Nonselective and ETA-selective receptor antagonists did not prevent the early peak but 
efficiently prevented the late peak, indicating that the late phase of the Ang II-induced 
superoxide production is ET-1 dependent whereas the early phase is independent of ET-1 
(Laplante et al., 2005). Furthermore, blockade of ETA receptors suppressed the AngII-
induced expression of Nox1 and Nox4, two homologs of the p91phox (NOX2) subunit 
expressed in VSMCs (Laplante et al., 2005). Cingolani et al. (2006) reported that AngII-
induced ROS production in cat ventricular myocytes was completely abolished by 
nonselective ET-1 receptor blocker TAK044 and the selective ETA receptor blocker BQ-
123, which argues for the crucial role of ET-1 in AngII-induced ROS production in 
cardiomyocytes.   
AngII exerts a positive inotropic effect on cardiac muscle by increasing the 
intracellular Ca2+ transient (Petroff et al., 2000; Salas et al., 2001).  ET receptor blockers 
abolished exogenous AngII-induced inotropic effects, indicating that the inotropic effect 
of AngII is mediated by ET-1 (Perez et al., 2003; Cingolani et al., 2006). The slow force 
response to myocardial stretch is ascribed to an autocrine/paracrine release of AngII and 
ET-1 (Cingolani et al., 1998; Cingolani et al., 2001). Blockade of ETA receptors or AT1 
receptors canceled strech-induced NHE-1 activation and inotropic effect. The direction of 
the cross-talk between AngII and ET-1 was demonstrated by the findings that ETA 
receptor blockade blunted the activation of NHE-1 by exogenous Ang II, whereas AT1 
receptor blockade was unable to block the effect of ET-1, which suggests that AngII is 
upstream from ET-1 (Cingolani et al., 1998; Cingolani et al., 2001; Perez et al., 2003). 
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 Both AngII and ET-1 exhibit potent growth-promoting effect on vasculature and 
cardiac tissue. Both in vitro and in vivo studies have suggested that ET-1 is involved in 
hypertrophic changes induced by AngII. Ito et al. (1993) and Xia et al. (2004) showed 
that AngII upregulated ppET-1 mRNA expression in cultured neonatal rat 
cardiomyocytes, and inhibition of ET-1 signaling by ETA receptor antagonist or antisense 
sequence against coding region of ppET-1 mRNA blunted hypertrophic response induced 
by AngII. Moreau et al. (1997) demonstrated that selective ETA-receptor antagonists 
prevented chronic AngII infusion-induced hypertrophic changes of vasculature. Ficai et 
al. (2001) showed that non-selective ET receptor antagonist bosentan prevented cardiac 
hypertrophy evoked by chronic Ang II infusion. Endogenous ET-1 also was shown to act 
as a downstream mediator for AngII in the development of cardiac hypertrophy in 
response to volume overload (Ishiye et al., 1995a; Ishiye et al., 1995b). The role of ET-1 
in AngII-induced hypertrophy response was further supported by transgenic animal 
models.  In transgenic rats harboring both human renin and human angiotensinogen genes 
(dTGR), the non-selective ET receptor antagonist SB 209670 significantly attenuated 
both cardiac hypertrophy and vascular wall thickening (Maki et al., 2004) . 
 Both AngII and ET-1 are important pro-fibrotic and pro-inflammatory factors. It 
has been shown that AngII induces ppET-1 gene expression in both vascular (An et al., 
2007) and  cardiac fibroblast (Cheng et al., 2003). In dTGR mice that overexpress renin 
and angiotensinogen, endothelin converting enzyme (ECE) inhibitor treatment 
significantly reduced  fibrosis in the vessel wall and cardiac tissue (Muller et al., 2002). 
Another study using this transgenic model showed that non-selective ET receptor 
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antagonist bosentan inhibits NFκB and AP-1 activation as well as inflammatory gene 
expression regulated by these two transcription factors, suggesting that ET-1 is involved 
in Ang II-induced inflammation (Muller et al., 2000).  
 It has been well recognized that AngII is related to the genesis of ventricular 
arrhythmias under multiple pathological conditions, including hypertension, heart failure, 
ischemia, and acute myocardial infarction (for review, see Garg et al., 2006). Brunner 
and Kukovetz (1996) showed that the inhibition of reperfusion arrhythmias by 
Angiotension converting enzyme (ACE) inhibitors might be attributed to suppression of 
ET-1 secretion and action. ETA receptor antagonist ESB 209670 alone was equally anti-
arrhythmic as ACE inhibitors, and they both almost completely suppressed reperfusion 
arrhythmias. ICa,T reappears in hypertrophic ventricular cells, which may contribute to 
Ca2+ overload and triggered arrhythmias (Levine et al., 2000). AngII was shown to 
increase ICa,T density and CaV3.1 mRNA in cultured myocytes, and these effects are 
inhibited by non-selective ET receptor antagonist bosentan, suggesting that ET-1 may 
mediate AngII-induced ICa,T upregulation (Ferron et al., 2003). 
Numerous studies also have illuminated the crucial role of AngII in pathogenesis 
of atrial fribrillation (for review, see Healey et al., 2005). Although evidence indicating 
the interaction of AngII and ET-1 in genesis of atrial arrhythmias seems lacking right 
now, ET-1 is potentially a downstream mediator of AngII in the genesis of atrial 
fibrillation (AF). Presumably, the fast and irregular beating seen in AF would stretch 
atrial myocytes and trigger the autocrine/paracrine loop leading to sequential Ang II and 
ET-1 release, as discussed previously. ET-1 is elevated in plasma and tissue samples of 
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patients with AF (Tuinenburg et al., 1998; Brundel et al., 2001; Masson et al., 2006), and 
ET-1 has been shown to shorten APD in atrial cells (Yorikane et al., 1991; Ono et al., 
1994), which contributes to electrical remodeling of atria that facilitates reentry 
(Nakashima et al., 2000). In addition to electrical remodeling, the arrhythmogenic 
properties of Ang II in AF are also attributed to atrial structural remodeling (Okazaki et 
al., 2006; Everett & Olgin, 2007), oxidative stress (Korantzopoulos et al., 2007), and 
inflammation (Boos et al., 2006;Wachtell et al., 2007).  ET-1 may act as a downstream 
effector for AngII in all of these processes.  
1.6. Cardiac ICl,swell and its Regulation 
ICl,swell is a chloride current expressed in the heart and other cell types in many 
species including human (Hume et al., 2000). As suggested by the name, ICl,swell is 
activated by osmotic increase of cell volume. ICl,swell can also be activated by multiple 
stimuli under isosmotic conditions, including cell inflation (Hagiwara et al., 1992), 
anionic amphipaths (Tseng, 1992), β1-integrins stretch (Browe & Baumgarten, 2003), 
AngII (Browe & Baumgarten, 2004), EGF (Browe & Baumgarten, 2006), H2O2 (Browe 
& Baumgarten, 2004), and ET-1 (Du & Sorota, 2000).  ICl,swell was classified as a 
mechanosensitive channel because its open probability can be modulated by deforming 
membrane patch with pipette pressure (Sato & Koumi, 1998). However, aspects of the 
single channel currents identified by these authors are different than those reported by 
Duan and Nattel (1994). Although the biophysical characteristics, pharmacology, as well 
as the regulation pathways of cardiac ICl,swell have been intensively investigated, the 
molecular identity of this channel remains elusive.  
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 Several biophysical characteristics can be used to identify ICl,swell. ICl,swell is 
outwardly rectifying and reverses near ECl with either a physiological or symmetrical Cl 
gradient, and the current is time-independent over the physiologic voltage range but 
partially inactivates at strongly positive potentials (Duan et al., 1995; Shuba et al., 1996). 
On the other hand, the time-dependent component can be blocked (Ren & Baumgarten, 
2005). ICl,swell is independent of cytoplasm Ca2+  (Lemonnier et al., 2002; Zholos et al., 
2005), and this channel is also permeant to other anions with the permeability sequence: 
I− > NO3− > Br− > Cl− > Asp− (Hagiwara et al., 1992; Vandenberg et al., 1994). 
 Early studies of the pharmacology of cardiac ICl,swell were made by Sorota et al. 
(1994). ICl,swell is insensitive to Gd3+ (Clemo & Baumgarten, 1997), which is a blocker of 
cation mechanosensitive channels. Tamoxifen and DIDS (4,4′-diisothiocyanostilbene-2, 
2′- disulfonic acids) emerged as useful tools to identify ICl,swell under conditions that 
isolate anion currents, but they also inhibit multiple cation channels and transporters (for 
review, see Baumgarten & Clemo, 2003). DCPIB [4-(2-butyl-6,7-dichloro-2- 
cyclopentyl-indan-1-on-5-yl) oxobutyric acid)], which only recently became 
commercially available, is a highly selective ICl,swell blocker. It does not inhibit either 
CFTR or Ca2+-activated Cl- channels(ICl,Ca ) and also has no effect on several K+, Ca+, 
Na+ channels (Decher et al., 2001).  
  ICl,swell influences cardiac electric activities and acts as a potential effector of 
mechanoelectrical feedback that  antagonizes the effects of stretch-activated cation 
channels (Baumgarten & Clemo, 2003). As ICl,swell reverses between the resting and 
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plateau potentials of cardiomyocytes, activation of ICl,swell depolarizes membrane 
potential (Em) and shorten APD (Hiraoka et al., 1998; Decher et al., 2001). 
 Activation of ICl,swell has been observed in multiple cardiovascular abnormalities, 
including dilated cardiomyopathy induced by rapid pacing (Clemo et al., 1999b) or aortic 
regurgitation (Clemo & Baumgarten, 1998; Clemo et al., 1999a), myocardial infarction 
(Clemo et al., 2001), and in human atrial myocytes from patients with atrial enlargement 
or elevated ventricular end-diastolic pressure (Patel et al., 2003). Based on its biophysical 
properties, ICl,swell has profound implication in arrhythmogenesis. APD abbreviation 
resulting from ICl,swell activation would dampen afterdepolarizations and protect against 
triggered arrhythmias, on the other hand, it favors reentry arrhythmias such as AF. 
 In addition to the effects on cardiac electric activities, ICl,swell is closely related to 
multiple physiological and pathophysiological processes, including cell volume 
regulation, proliferation, differentiation , migration, apoptosis, ischemia-reperfusion-
induced death of cardiomyocytes (for review, see Okada et al., 2009).   
 Previous studies indicated that H2O2, the longer lived, membrane permeable ROS, 
appears to be a regulator of ICl,swell. Exogenous H2O2 elicites a current with exactly same 
properties as ICl,swell and scavenging H2O2 with catalase precludes activation of ICl,swell 
(Browe & Baumgarten, 2004; Ren et al., 2008). Studies over the last decade have 
indicated that the NOX family of enzymes is the major source of ROS in the 
cardiovascular system (for review, see Griendling, 2006). Activation of ICl,swell in 
response to integrin stretch and osmotic swelling was blocked by inhibitors of NOX 
(Browe & Baumgarten, 2004; Ren et al., 2008). Besides NOX, mitochondria are also 
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important source of ROS in cardiomyocytes and recently the crosstalk between NOX and 
mitochondria has emerged as a new concept of cellular signaling(Kimura et al., 2005a; 
Kimura et al., 2005b; Caldiz et al., 2007).  
1.6.1. NOX-Derived ROS and Upstream Mediators  
1.6.1.1. Integrin, FAK, and Src  
 Since ICl,swell is a mechanosensitive current, how the mechanical forces are sensed 
and transmitted would be of importance. As the physical links between the extracelluar 
matrix (ECM) and cytoskeleton, integrins are the best candidates for the mechanosensors 
(Force et al., 2002; Manso et al., 2006). Integrins colocalize with a variety of signaling 
molecules, adaptor proteins, and other cell surface receptors within costameres, among 
which are focal adhesion kinase (FAK) and members of the Src kinase family (Ross, 
2002; Shai et al., 2002; Ross, 2004). FAK and Src are well positioned to be the principal 
upstream PTKs mediating the integrin-induced mechanotrasduction (Brancaccio et al., 
2006; Lal et al., 2007). FAK binds to the cytoplasmic domain of 1-integrin and 
autophosphorylates at Y397. Src binds to Y397 of FAK via its SH2 domain. Activated 
FAK and Src recruit a number of signaling molecules, including PKC, PI-3K, protein 
phosphatases, small GTPases and trigger a network of downstream signaling cascades 
(Pham et al., 2000; Parsons, 2003). 
 The principle integrin isoform in heart is 1D (Ross et al., 1998). The roles of 1-
integrins and its downstream FAK and Src in the regulation of ICl,swell are evidenced by 
the findings that 1-integrin stretch elicited ICl,swell under isosmotic conditions (Browe & 
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Baumgarten, 2003).  Both the non-specific PTK inhibitor genistein and selective FAK/Src 
blocker PP2 fully inhibited 1-integrin stretch-induced ICl,swell (Browe & Baumgarten, 
2003).  
 The role of Src in the regulation of ICl,swell apparently differs between stimuli. In 
contrast to its inhibition of the response to integrin stretch, the Src family PTK inhibitor 
PP2 substantially augment ICl,swell induced by osmotic swelling in atrial and ventricular 
myocytes (Du et al., 2004; Ren & Baumgarten, 2005). This was confirmed by Walsh and 
Zhang (Walsh & Zhang, 2005), who reported that both PP2 and expression of FAK-
related non-kinase (FRNK), which acts as a FAK inhibitor, both enhanced the activation 
of ICl,swell upon osmotic swelling of cultured neonatal rat ventricular myocytes. The 
mechanisms underlying the differential regulation of ICl,swell by FAK and Src inhibitors 
are not understood.  
1.6.1.2. AngII and AngII Receptor 
 A well-recognized effect of mechanical stretch is releasing paracrine/autocrine 
factors including AngII and ET-1, which interact with their receptors on cardiomyocytes 
and orchestrate various downstream signaling pathways (Sadoshima et al., 1993; van 
Wamel et al., 2000; van Wamel et al., 2001). Meanwhile, mechanical stretch can activate 
AngII receptor type 1 (AT1R) without AngII binding, suggesting that AngII release may 
not be mandatory for AT1R activation (Zou et al., 2004; Akazawa et al., 2006).  
 The role of AngII and AT1R in the regulation of ICl,swell is supported by 
observations that exogenous AngII elicits ICl,swell under isosmotic conditions and that 
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AT1R competitive antagonists, losartan and eprosartan blocked 1 integrin stretch- and 
osmotic swelling- induced ICl,swell (Browe & Baumgarten, 2006; Ren et al., 2008).  
1.6.1.3. EGFR Kinase 
 Previous studies have established that EGFR is a common element in the 
signaling pathways activated by cell volume changes (Lezama et al., 2005), integrins 
(Moro et al., 2002), AT1 receptors (Shah & Catt, 2003), and ETA receptors (Prenzel et al., 
1999; Kodama et al., 2002; Anderson et al., 2004). Upon activation, EGFR translocates 
from caveolae to costameres, recruits and phosphorylates various downstream signaling 
molecules (Shah, 2002).  
 EGFR also are implicated in the regulation of ICl,swell (Du et al., 2004; Browe & 
Baumgarten, 2006; Ren et al., 2008).  EGFR kinase blockers inhibit activation of ICl,swell 
by osmotic swelling, 1 integrin stretch, and AngII, while exogenous EGF elicits ICl,swell 
under isosmotic conditions (Browe & Baumgarten, 2006; Ren et al., 2008). 
1.6.1.4 PI-3K  
 PI-3K are heterodimers composed of a p110 catalytic subunit and a regulatory 
subunit. The predominant PI-3K isoforms expressed in the cardiac myocytes are p110-
p85 and p110-p101, which are activated by PTK and  subunits of G proteins, 
respectively (Kessler et al., 2001; Crackower et al., 2002). It has been demonstrated that 
PI-3K is activated by myocardial stretch, osmotic swelling, and integrin clustering 
(Bewick et al., 1999; Petroff et al., 2001; Torsoni et al., 2003). In cardiomyocytes, PI-3K 
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couples to EGFR and mediates the downstream signaling of EGFR and AT1 receptors 
(Seshiah et al., 2002; Oudit et al., 2004).  
 PI-3K inhibitors including wortmannin and LY294002 suppress EGF-, 1 integrin 
stretch-, and osmotic swelling-induced ICl,swell, suggesting that PI-3K lies downstream 
from EGFR in the signaling cascade leading to ICl,swell activation (Browe & Baumgarten, 
2006; Ren et al., 2008).    
1.6.1.5. NOX  
 The predominant NOX isoform expressed in cardiac myocytes is NOX2, and the 
expression of NOX4 is  also reported (Byrne et al., 2003). NOX2 is composed of several 
components: a transmembrane flavocytochrome b558 complex consisting of a large 
gp91phox (Nox2) and a smaller p22phox subunit, cytosolic p47phox and p67phox subunits, and 
the small GTP-binding protein Rac (Vignais, 2002; Murdoch et al., 2006; Sirker et al., 
2007). To make NOX2 functional, the cytosolic subunits and Rac need to translocate 
from cytosol to the membrane and assemble with gp91phox and p22phox. This process 
involves multiple signaling molecules, including PKC, Src and other PTKs, and PI-3K 
(Vignais, 2002; Murdoch et al., 2006; Sirker et al., 2007). The fully assembled NOX2 is 
able to transfer electron across the membranes, i.e. from intracellular NADPH or NADH 
as electron donors to extracellular molecular oxygen, to form O2−, which is rapidly 
converted to H2O2 both spontaneously and by superoxide dismutase (SOD) (Vignais, 
2002).  
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 PI-3K has been shown to participate in the activation of NOX and the generation 
of ROS in response to diverse stimuli in several tissues (Hawkins et al., 2007). NOX is 
essential for activation of ICl,swell in response to 1 integrin stretch, AngII, EGF, and 
osmotic swelling. Blocking NOX with diphenyleneiodonium (DPI), 4-(2-aminoethyl) 
benzenesulfonyl fluoride (AEBSF), apocynin or a membrane-permeant fusion peptide 
inhibitor of NOX assembly (gp91ds-tat) rapidly and completely blocked ICl,swell induced 
by 1 integrin stretch, AngII, EGF, and osmotic swelling (Browe & Baumgarten, 2006; 
Ren et al., 2008).  
1.6.2 Mitochondria-Derived ROS and Upstream Mediators  
 Besides NOX, mitochondria are another source of ROS in cardiomyocytes. 
Excessive mitochondrial ROS production is observed in cardiomyocytes from 
experimental models of heart failure (Ide et al., 1999; Ide et al., 2000), myocardial 
infarction (Ide et al., 2001), and ischemia/reperfusion (Ambrosio et al., 1993). In addition 
to these pathological processes, recent studies indicate that mitochondrial-derived ROS 
are involved in the slow force response to myocardial stretch (Caldiz et al., 2007) as well 
as in the positive inotropic effects of AngII and ET-1 (Cingolani et al., 2006; De Giusti et 
al., 2008).  
 Acetylcholine (ACh) was shown to stimulate mitochondrial ROS production in 
ventricular myocytes via muscarinic receptors (Yao et al., 1999; Oldenburg et al., 2003). 
ACh-induced mitochondria ROS production is dependent on PI-3K, Src, mitochondrial 
ATP-sensitive K+ (MitoKATP ) channel opening (Oldenburg et al., 2003) and is mediated 
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by transactivation of EGFR through matrix metalloprotease-dependent release of HB-
EGF (Krieg et al., 2004). Therefore, ACh and AngII activate essentially the same 
signaling cascade leading to ROS generation, except that the sources of ROS are thought 
to be different (mitochondria vs. NOX). The role of mitochondrial ROS in the regulation 
of ICl, swell was indicated by the preliminary data showing that exogenous ACh elicits  
ICl, swell that is blocked by mitochondria KATP channel blocker and mitochondrial complex 
I inhibitor rotenone (Browe & Baumgarten, 2007). Additionally, we also showed that 
ICl,swell could be activated by mitochondrial ROS without the involvement of NOX (Deng 
et al., 2009; Raucci, Jr. & Baumgarten, 2009).  
1.6.3. Crosstalk between NOX and Mitochondria  
 The localization of NOX and the subsarcolemmal mitochondria in the 
cardiomyocytes raise the feasibility of their crosstalk, and there is some evidence 
indicating the interaction between NOX and mitochondria in ROS generation and ROS-
dependent effects. AngII and ET-1 induce both NOX and mitochondrial ROS production 
(Seshiah et al., 2002; Kimura et al., 2005a; De Giusti et al., 2008). Inhibition of NOX or 
blockade of mitoKATP channel abrogated exogenous AngII- induced ROS production, 
activation of MAPK pathway, inotropic response, preconditioning, lipid peroxidation and 
apoptosis of cardiomyocytes (Kimura et al., 2005b; Zhang et al., 2007; Caldiz et al., 
2007). A recent study also showed that blockade of either NOX or mitoKATP channel 
abolished ET-1-induced ROS production and inotropic effect (De Giusti et al., 2008). 
Complete abrogation by blockade of either source of ROS indicates that NOX and 
mitochondria act in serial rather than in parallel.  
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 The underlying mechanism by which NOX interacts with mitochondria has not 
been illuminated. One possibility is that ROS produced by NOX directly modify and 
open mitochondria KATP channels (Zhang et al., 2001). Another possibility is ROS-
induced ROS release (Zorov et al., 2000).  
1.6.4. PKC, Rho/Rho Kinase, and ERK1/2  
 Besides ROS and its known upstream mediators, regulation of ICl,swell by PKC,  
Rho/Rho Kinase  and ERK1/2 were also reported. The regulation of ICl,swell by PKC was 
attributed to the channel itself, i.e. the open probability of the channel was thought to be 
regulated by the phosphorylation state of the channel protein at a PKC consensus site 
(Hume et al., 2000). Rho and Rho kinase were shown to exert a permissive effect on the 
activation of ICl,swell (Tilly et al., 1996b; Nilius et al., 1999). Previous studies also indicate 
that MAPK pathway plays a role in the regulation of ICl,swell. Selective blocker of ERK1/2 
inhibited ICl,swell in ventricular myocytes from failing canine hearts (Clemo & 
Baumgarten, 1999) and the potentiation of ICl,swell by ET-2 (Du & Sorota, 2000).  
1.7. Potential Role of ET-1 in the Regulation of ICl,swell 
 ET-1 potentially is a downstream mediator of 1 integrin and AngII AT1 receptor 
signaling in the regulation of ICl,swell. ET-1 is released by myocardial stretch and plays an 
critical role in stretch-induced cardiac hypertrophy (van Wamel et al., 2000; van Wamel 
et al., 2001; Cingolani et al., 2008) and stretch-induced inotropic effect (Alvarez et al., 
1999; Cingolani et al., 2001; Aiello et al., 2002; Cingolani et al., 2003; Cingolani et al., 
2005). Both synthesize and release of ET-1 can be stimulated by AngII, and there is 
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evidence that ET-1 mediates AngII-induced ROS production and inotropic response in 
cardiomyocytes (Cingolani et al., 2006; Villa-Abrille et al., 2006)  
Although stimulatory effects of ET-1 and ET-2 on cardiac ICl,swell have been 
reported (Du & Sorota, 2000), the signaling cascades that links ET to ICl,swell has have not 
been determined. ET-1 induces NOX activation and ROS generation in various cell types 
including cardiomyocytes (Cheng et al., 1999; Duerrschmidt et al., 2000; Callera et al., 
2003; Li et al., 2003; Amiri et al., 2004; Cingolani et al., 2006), and ET-1 also activates 
EGFR kinase and PI-3K (Pierce et al., 2001; Pham et al., 2001; Kodama et al., 2002; 
Sugden, 2002), which were shown to be upstream regulators of NOX in the activation of 
ICl,swell by β1 integrin stretch, AngII, and osmotic swelling (Browe & Baumgarten, 2006; 
Ren et al., 2008). We therefore propose that ET-1 elicits ICl,swell via a signaling cascade 
that involves EGFR kinase, PI-3K, NOX, and ROS.  
 ET-1 activates ERK1 and ERK2 in cardiomoycytes (Bogoyevitch et al., 1993; 
Bogoyevitch et al., 1994). ERK1/2 blockade inhibited the persistent activation of ICl,swell 
in the failing heart (Clemo & Baumgarten, 1999) and ET-2- induced potentiation  of 
ICl,swell (Du & Sorota, 2000). NOX activation in response to AngII and other stimuli was 
shown to be dependent on ERK1/2 in non-cardiac cells (Laplante et al., 2003; Hazan-
Halevy et al., 2005; Lo et al., 2005). Whether ERK is involved in the activation of NOX 
by ET-1 in cardiomyocytes and how ERK is involved in the pathway that regulates 
ICl,swell remain to be determined.  
 Besides eliciting ROS generation by NOX, ET-1 also induced mitochondrial ROS 
production, and mitochondrial source of ROS has been implicated in the inotropic effect 
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of ET-1 (Touyz et al., 2004; De Giusti et al., 2008). Blocking either NOX or mitoKATP 
channel cancelled ET-1-induced ROS production and positive inotropic effect, suggesting 
that NOX and mitochondria act in serial rather than parallel pathways (De Giusti et al., 
2008). Furthermore, our preliminary data show that mitochondrial ROS is involved in the 
regulation of ICl,swell (Browe & Baumgarten, 2007; Deng et al., 2009; Raucci, Jr. & 
Baumgarten, 2009). Nevertheless, the role of mitochondrial ROS in the activation of 
ICl,swell by ET-1 and the potential interaction between NOX and mitochondria in this 
process have not been elucidated.  
1.8. HL-1 Cells as a Potential Tool to Investigate ICl,swell 
 HL-1 cell are an immortalized mouse atrial muscle cell line derived from a 
primary culture of SV40 large T antegen-induced atrial tumors. This cell line can be 
repeatedly passaged, while maintaining their ability to contract and retaining 
differentiated cardiac morphological, biochemical, and electrophysiological properties 
(Claycomb et al., 1998). HL-1 cells have been used to study cellular signaling, calcium 
handling, and electrical properties of cardiomyocytes (McWhinney et al., 2000; Sartiani 
et al., 2002; Akhavan et al., 2003; George et al., 2003; Walker et al., 2007). They have 
also been used in various pathological models, including hypoxia (Cormier-Regard et al., 
1998; Nguyen & Claycomb, 1999), apoptosis (Kitta et al., 2001a; Kitta et al., 2001b; 
Carlson et al., 2002; Kim et al., 2003), ischemia-reperfusion (Ruiz-Meana et al., 2003; 
Suzuki et al., 2004; Mirabet et al., 2005; Andersen et al., 2009), and electrical 
remodeling induced by rapid pacing (Yang et al., 2005). 
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 Previous studies showed that renin-angiotensin system component are expressed in the 
HL-1 cells (Tsai et al., 2008) and that AngII induces expression of L-type calcium 
channels via a NOX-ROS  dependent pathway (Tsai et al., 2007). It also has been 
demonstrated that ET-1 induces activation of the cardiac transcription factor GATA-4 and 
expression of connective tissue factor, suggesting that functional ET receptor-mediated 
signaling is maintained (Kitta et al., 2001a; Recchia et al., 2009). 
 No information is available regarding Cl channels in HL-1 cells.  If ICl,swell is 
present in HL-1 cells and is regulated by similar mechanism as in native cells, this 
immortalized cardiac cell line would be a valuable tool for understanding ICl,swell at the 
molecular level. 
1.9. Aims of the Present Study 
There were four principle aims for the present study. The first aim was to 
determine the signaling cascade by which ET-1 activates ICl,swell. The roles of ET receptor 
subtypes, EGFR kinase, PI-3K, ERK, NOX, and ROS were evaluated.  The second aim 
was to examine the interaction between NOX and mitochondria in the ET-1-induced 
activation of ICl,swell and to determine if these sources of ROS acted in parallel or in series. 
The third aim was to determine whether ET-1 signaling cascade that regulates ICl,swell is 
downstream from AngII and osmotic swelling or whether it represents a parallel but 
independent pathway. The fourth aim was to determine whether ICl,swell is present in HL-1 
cells and whether ICl,swell is regulated by the same mechanism as in native cells. 
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Chapter 2 
MATERIALS and METHODS 
 
 
2.1. Rabbits and Atrial Myocyte Isolation     
Atrial myocytes were freshly isolated from adult New Zealand white rabbits (2.8 
– 3.1 kg) of either gender by a pronase-collagenase enzymatic dissociation method. 
Rabbits were anesthetized with dual intramuscular (i.m.) injections; first a sedative dose 
of 0.2 ml xylazine HCl (100 mg/ml) administered in combination with 1.0 ml 
acepromazine maleate (10 mg/ml), followed by an anesthetic dose of 2.5 ml ketamine 
HCl (100 mg/ml). Hearts were excised, immediately tied via the aorta to the end of a 
Langendorff column, and retrogradely perfused for 5 minutes with Tyrode solutions that 
were oxygenated and maintained at 37°C, followed by 5 minutes with a “Ca2+-free” 
Tyrode solution, and then, the heart was perfused with enzyme solution for ~20 minutes. 
Atria were excised, minced, and placed in fresh enzyme solution. The tissues were 
bubbled with O2 and gently shaken for two 15-minute cycles in a 37°C shaker bath. At 
the end of each cycle the supernatant was collected and replaced with fresh enzyme 
solution. The supernatants were filtered through 200 µm nylon mesh (Small Parts, Miami 
Lakes, FL), and isolated cells were pelleted by gentle centrifugation. Isolated myocytes 
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were washed twice and stored in a modified Kraft-Brühe solution (pH 7.2) before using. 
Rod-shaped quiescent cells with clear striations and no membrane blebs or other 
morphological irregularities were studied within 10 hr of isolation. 
Tyrode solution for myocyte isolation contained (mM): 130 NaCl, 5 KCl, 1.8 mM  
CaCl2, 0.4 KH2PO4, 3 MgCl2, 5 HEPES, 15 taurine, 5 creatine, 10 glucose, pH 7.25 
(adjusted with NaOH). For “Ca2+-free” Tyrode solution, CaCl2 was replaced with 0.1 
mM Na2EGTA. For making enzyme solution, the “Ca2+-free” Tyrode solution was 
supplemented with 0.45 mg/ml collagenase (Cls 4; Worthington Biochemical, Lakewood, 
NJ), and 0.015 mg/ml pronase (Type XIV; Sigma-Aldrich, St. Louis, MO). The modified 
KB myocyte storage solution contained (mM): 120 K-glutamate, 10 KCl, 10 KH2PO4, 0.5 
K2EGTA, 10 taurine, 1.8 MgSO4, 10 HEPES, 20 glucose, 10 mannitol, pH 7.2 (adjust 
with KOH).   
2.2. Culture of HL-1 cells  
HL-1 cardiac myocytes (passage 3 to 17), an immortalized mouse atrial cell line 
(Claycomb et al., 1998), were also studied.  Tissue culture flasks first were coated with 
gelatin (0.02%)/fibronectin (0.5%) (2 ml in T25 or 6 ml in T75 flask) and incubated at 
37°C overnight. HL-1 cells were cultured in pre-coated flasks using Claycomb medium 
(JRH Biosciences, Lenexa, KS) supplemented with 10% fetal bovine serum (Sigma-
Aldrich), 100 μg/ml penicillin/streptomycin, 0.1 mM norepinephrine (Sigma-Aldrich) 
and 2 mM L-glutamine (Invitrogen, Carlsbad, CA). The cells were kept at 37°C in an 
atmosphere of 5% CO2 and 95% air at a relative humidity of approximately 95%. Once 
the HL-1 cells reached confluence, the cells were passaged by spliting 1 to 2. To split the 
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cells, the cells were rinsed briefly with DPBS and then incubated with 0.05% 
trypsin/EDTA (3 ml for T25, 6 ml for T75 flask) at 37°C for 3 – 5 min until the cells 
were disloged. Equal amount of soybean trysin inhibitor (25 mg/100 ml PBS) was added 
directly into the cells and the cells were transferred into a 15 ml centrifuge tube and 
centrifuged at 1100 rpm for 5 min. The supernatant was removed by aspiration and the 
pellet was gently suspended in 3 ml of supplemented Claycomb medium. The cells were 
transfer into gelatin/fibronectin-coated flasks for culturing or 15 ml centrifuge tube for 
electrophysiological studies. 
2.3. Experimental Solutions and Drugs 
Anion currents were recorded in Na+, K+, and Ca2+-free bath solution with 
equimolar replacement of Na+ and K+ with N-methyl-D-glucamine (NMDG+), while 
CaCl2 was replaced with MgCl2. In the Na+ and K+-free pipette solution used for 
recording anion currents, Na+ and K+ were replaced with equimolar amounts of Cs+. Bath 
solution contained (mM): 90 N-methyl-D-glucamine (NMDG)-Cl, 3 MgCl2, 10 HEPES, 
10 glucose, 5 CsCl, 0.5 CdCl2 pH 7.4 (adjusted with CsOH), 70 mannitol and was 
isosmotic (300 mOsm/L; 1T). Mannitol was omitted in hyposmotic solutions to reduce 
osmolarity to 0.7-times (0.7T) that in isosmotic solutions, reduced to 35 mM to make 
0.85T solution, and increased to 220 mM to make 1.5T hyperosmotic solution. By 
varying the mannitol concentration, solution osmolarity was adjusted at a constant ionic 
strength and avoided unintended alteration of ion activities. Pipette solution contained 
(mM): 110 Cs-aspartate, 20 CsCl, 2.5 Mg-ATP, 8 Cs2-EGTA, 0.1 CaCl2, 10 HEPES, pH 
7.1 (adjusted with CsOH; liquid junction potential, −15 mV).  The pipette free-Ca2+ was 
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~35 nM (WinMAXC ver 2.4; www.stanford.edu/~cpatton/maxc.html). ICl,swell is 
essentially time-independent under these conditions (Ren & Baumgarten, 2005). Pipette 
and bath solution osmolarities were verified by freezing-point depression.   
Endothelin-1 (200 µM, Calbiochem/EMD, Gibbstown, NJ) was prepared as stock 
solutions in 5% acetic acid and kept frozen (−20°C) in small aliquots until use. 
Angiotensin II (5 µM, Calbiochem) and BQ123 (1 mM) were dissolved in H2O and kept 
frozen (−20°C). Stock solutions of BQ788 (100 µM, Calbiochem), AG1478 (1 mM, 
Calbiochem), wortmannin (1 mM, Calbiochem), LY294002 (50 mM, Calbiochem), 
PD98059 (10 mM, Calbiochem), U0216 (1 mM, Biomol International/Enzo Life 
Sciences, Plymouth Meeting, PA), ebselen (15 mM, Calbiochem), rotenone (20 mM, 
Sigma-Aldrich), diazoxide (4.33 mM, Sigma-Aldrich), and antimycin A1 (20 mM, 
Sigma-Aldrich) were prepared in DMSO and frozen (−20°C) in small aliquots until use. 
EGF (3.3 µM, Calbiochem) and losartan (5 µM, Merck) were dissolved directly in bath 
solution and kept frozen (−20°C). The NOX inhibitor gp91ds-tat was synthesized by the 
Tufts University Core Facility, and the peptide stocks (1.2 mg/ml) were made in 150 mM 
NaCl plus 10 mM acetic acid and frozen (−20°C) in aliquots until use. DCPIB (4-[2-
butyl-6,7-dicholo-2 cyclopenty1-2,3 -dihydro-1-oxo-1H-inden-5-yl) oxy] butanoic acid; 
20 mM; Tocris Bioscience, Ellisville, MO) was prepared as a stock solution in ethanol 
                                                 
1 Antimycin A contains four closely related components, antimycin A1 (538.6 Da), A2 
(534.6 Da), A3 (522.6 Da), and A4 (510.6 Da). Assays provided by Sigma-Aldrich 
indicated that the percentage of each component varied in the lots used: A1, 33 – 75%; 
A2, 19 – 20%; A3, 5 – 32%; A4, 10 – 18%. Therefore, solutions were prepared using the 
weighted average molecular weight.  
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and kept refrigerated (−4°C). A stock solution of apocynin (500 mM, Sigma-Aldrich) 
was prepared in DMSO and kept at room temperature until use.   
2.4. Whole Cell Patch Clamp and Electrophysiological Recordings 
Pipettes were manufactured from 7740 thin-walled borosilicate glass capillary 
tubing (1.5 mm o.d., 1.12 mm i.d., filament; Sutter Instrument, Novato, CA) using a P-97 
micropipette puller (Sutter Instrument) and then fire polished. The final pipette tip 
diameter was 2 – 3 µm, and the corresponding pipette resistance in bath solution was 2 – 
4 MW. Junction potentials were corrected, and a 3-M KCl-agar bridge served as the 
ground electrode. Freshly isolated atrial myocytes and HL-1 cells were dispersed over a 
glass bottomed cell chamber (~0.3 ml) mounted onto the stage of an inverted microscope 
(Diaphot; Nikon, Inc., Garden City, NY), and visualized with Hofmann modulation 
optics (40X; NA = 0.55) and a high resolution TV camera (CCD72; Dage-MTI; 
Michigan City, IN) that projected images onto a video monitor. A fluid flow system was 
attached to the cell chamber and bath solution was superfused at a rate of 2 – 3 ml/min. 
Typical seal resistances were 5 – 30 GΩ, and myocytes were dialyzed for at least 10 min 
before data were collected. Successive 500-ms steps were made from −60 mV to test 
potentials between −100 and +60 mV in +10 mV increments, and current-voltage (I–V) 
relationships were plotted from quasi steady-state currents. Currents were recorded with 
an Axoclamp 200B and Digidata 1322A under pClamp 9 (MDS Analytical Technologies, 
Sunnyvale, CA); they were digitized (5 kHz) after low-pass filtering (Bessel, 2 kHz) and 
were refiltered (Bessel, 500 Hz) in PClamp for presentation.   
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2.5. ROS Detection by Flow Cytometry 
ROS production was assessed in HL-1 cells rather than freshly isolated myocytes, 
which unavoidably include damaged myocytes in the preparation. ROS was detected with 
C-H2DCFDA-AM [6-carboxy-2',7'-dichlorodihydro-fluorescein diacetate di(acetoxy-
methyl ester)] (Invitrogen), which is converted into a non-fluorescent derivative 
(carboxy-H2DCF) by intracellular esterases. Carboxy-H2DCF is retained in the cytoplasm 
and is oxidized to fluorescent carboxy-DCF by intracellular ROS. Confluent cells were 
incubated with C-H 2 DCFDA-AM (5 µM) for 30 min at 37 °C, washed twice with 
DPBS, and then isolated using the splitting procedure.  Single myocytes suspensions in 
DPBS were analyzed using an EPICS XL cytometer (Beckman Coulter).  The geometric 
means of gated fluorescence distributions (excitation: 485nm; emission: 520 nm) were 
calculated using the EXPO32 software (Beckman Coulter).  After gating, 30,000 to 
40,000 cells contributed to each flurorescence distribution. Florescence histograms (1024 
bins) were exported to Excel (Microsoft) and plotted in SigmaPlot (Systat) after filtering 
(5 point running average, replotted in 512 bins); this gave plots that were comprable to 
those displayed with the commonly used smoothing function in EXPO32. 
2.6. Statistics 
Data are reported as mean ± SEM; n denotes the number of cells. Mean currents 
are expressed as current density (pA/pF) to account for differences in myocyte surface 
membrane area. One-way repeated-measures ANOVA were performed, and pairwise 
comparisons were made by the Holm-Sidak method with an overall significance level of 
37 
 
 
P <0.05 in SigmaStat 3.11 (Systat). For clarity, percent block (±SEM) of the drug-
activated current is reported for several interventions and was calculated using each 
myocyte as its own control. Non-linear fitting of current activation was done in 
SigmaPlot10.1 (Systat). Some of the florescence histograms data were not normally 
distributed and were analyzed using Kruskal-Wallis One Way Analysis of Variance on 
Ranks followed by pairwise comparisons by Dunn's method in SigmaStat.  These data are 
plotted using a box plot to denote the 25%, 50%, and 75% percentiles and error bars to 
denote the 10% and 90% percentiles. 
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Chapter 3 
RESULTS IN ADULT RABBIT ATRIAL MYOCYTES 
 
 
3.1. ET-1 Activates an Outwardly Rectifying Cl-current with Properties of ICl,swell 
Exposure to 10 nM ET-1 for 10 min elicited an outwardly rectifying Cl current 
that reversed near ECl (-43 mV). Families of membrane currents (Fig. 1A) and the 
corresponding IV relationships (Fig. 1B) from typical recordings are shown. ET-1- 
induced currents were abolished by DCPIB (Fig.1 A, B), a highly selective ICl,swell 
inhibitor (Decher et al., 2001). Fig. 1C presents summary data from cells exposed to 
DCPIB in continued presence of ET-1.  ET-1 (10 nM, 10 min) increased the outward Cl− 
current at +60 mV from 0.54 ± 0.04 to 1.69 ± 0.09 pA/pF (n = 57, P <0.001). Addition of 
DCPIB (10 μM, 6–12 min) with continued presence of ET-1 inhibited 99 ± 4% (n = 5, P 
<0.001) of ET-1-induced current at +60 mV, and the current after DCPIB application was 
not significantly different from the control currents (n = 5, P = 0.84). 
Volume sensitivity is one of the important characteristics of ICl,swell. ET-1- 
induced current was abrogated by osmotic shrinkage with 1.5- times isomotic (1.5T) 
solution (Fig.1 D, E, F). Application of 1.5T solution containing ET-1 decreased the ET-
1-induced Cl current at +60 mV from 1.79 ± 0.39 to 0.74 ± 0.22 pA/pF, an inhibition of 
96 ± 6% (n = 4, P <0.001).
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Figure 1:  ET-1 activated ICl,swell in atrial myocytes.  ET-1-induced Cl
-current was 
outwardly rectifying and suppressed by DCPIB, a highly selective ICl,swell blocker, 
and by osmotic shrinkage in 1.5-times isosmotic (1.5T) bath solution.  (A, D) Families 
of currents before and after exposure to ET-1 (10 nM, 10 min) and after addition of 
DCPIB (10 μM, 5-10 min; A) or osmotic shrinkage in 1.5T (5-10 min, D) bath in the 
continued presence of ET-1.  (B, E) I-V relationships for A and D.  Kinetics of fractional 
activation of ET-1-induced current (B, Inset).  Data for each experiment were 
individually fitted to sigmoidal relationship, Y = 1/(1+exp(-(x-x0)/b)), which gave 5.05  
0.46 for half-time for activation (x0) and 1.51  0.15 for slope factor (b).  At +60 mV, 
ET-1-induced current was 1.2 ± 0.1 pA/pF (n = 57).  (C, F) Normalized current from 
cells exposed to DCPIB and 1.5T solution in continuous presence of ET-1. DCPIB 
blocked 99.4 ± 3.6% (n = 5, P < 0.01) and osmotic shrinkage 95.4 ± 5.7% (n = 4, P < 
0.01) of current elicited by ET-1. 
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3.2. ET-1 Aactivated ICl,swell via ETA but not ETB Receptors 
  
ET-1-induced Cl- current was suppressed by selective ETA blocker BQ123 but not 
by ETB blocker BQ 788 (Fig. 2). Addition of BQ 123 (10 µM, 10 min) with continued 
presence of ET-1 reduced the current at +60 mV from 1.37 ± 0.22 pA/pF to 0.57 ± 0.08 
pA/pF, a value that was not significantly different from the control (n = 4, P =0.65). At 
+60 mV, BQ123 inhibited ET-1 induced currents by 90 ± 3% (n = 4, P < 0.01), indicating 
that ET-1-induced current required activation of ETA receptors. In contrast, the selective 
ETB blocker BQ 788 (100 nM, 15 – 20 min) had no effect on the ET-1-induced current (n 
= 4, P = 0.84). 
3.3. EGFR Kinase Regulates ET-1-induced ICl,swell    
Based on evidence that EGFR kinase is activated by  ET-1 in cardiomyocytes 
(Kodama et al., 2002) and its role in the activation of ICl,swell (Browe & Baumgarten, 
2006; Ren et al., 2008), we hypothesized that ET-1 elicited ICl,swell via EGFR kinase. We 
tested the role of EGFR kinase in ET-1-induced activation of ICl,swell using the selective 
EGFR kinase inhibitor AG1478. Fig.3 shows the normalized current of the cells that were 
exposed to ET-1 (10 nM, 10 min) and after addition of AG1478 (10 μM, 5 – 10 min) in 
the presence of ET-1. AG1478 (10 μM, 10 – 15 min) inhibited  the ET-1-induced Cl− 
current by 88 ± 3% (n = 5, P < 0.01), reducing outward Cl- current at +60 mV from to 
0.50 ± 0.16 to 1.83 ± 0.47 pA/pF, and the current after application of AG1478 (0.64 ± 
0.17 pA/pF) was not significantly different from the control (n = 5, P = 0.63).  
3.4. PI-3K is Involved in the Activation of ICl,swell  Induced by  ET-1  
There is evidence that EGFR kinase couples to PI3K (Shah et al., 2006) and PI-
3K is involved in the regulation of ICl,swell by β1-integrin stretch and osmotic swelling  
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Figure 2:  ET-1 activated ICl,swell via ETA but not ETB receptors.  (A, D) Family of 
currents before and after exposure to ET-1 (10 nM, 10 min) and after addition of selective 
ETA blocker BQ123 (10 μM, 5-10 min; A) or ETB blocker BQ788 (100 nM, 15 – 20 min, 
D) in the presence of ET-1.  (B, E) I-V relationships for A and D. (C, F) Current 
densities at +60 mV.  ETA blocker BQ123 suppressed 90.5  2.5% (n = 4, P < 0.01) of 
ET-1-induced ICl,swell, but ETB blocker BQ788 was ineffective (n = 4, P = 0.84).  
Signaling cascade is summarized in insets. The cascade denoted by  was excluded. 
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Figure 3:  EGFR kinase and PI-3K were downstream from ET-1 in the signaling 
cascade leading to ICl,swell.  After ICl,swell was activated by ET-1 (10 nM, 10 min), the 
EGFR kinase blocker AG1478 (10 µM, 10 – 15 min) or the PI-3K blockers LY294002 
(20 µM, 10 – 15 min) or wortmannin (500 nM, 8 – 15 min) were added in the continued 
presence of ET-1.  AG1478 reduced the current at +60 mV from 1.83 ± 0.47 pA/pF to 
0.64 ± 0.17 pA/pF (88.0 ± 3.0%; n = 5, P < 0.01), LY294002 from 1.63 ± 0.37 pA/pF to 
0.45 ± 0.07 pA/pF (101.9 ± 7.0%; n = 4, P < 0.01) and wortmannin from 1.62 ± 0.18 
pA/pF to 0.56 ± 0.05 pA/pF (91.7 ± 2.9%; n = 4, P < 0.01).  Signaling cascade is 
summarized in insert.  Previous studies (Browe & Baumgarten, 2006; Ren et al., 2008) 
demonstrated that EGFR is upstream from PI-3K and that PI-3K is upstream from ICl,swell. 
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(Browe & Baumgarten, 2006; Ren et al., 2008). To evaluate signaling molecules 
downstream from EGFR kinase, we tested whether PI-3K participates in the activation of 
ICl,swell in response to ET-1. LY 294002 and wortmannin are reversible and irreversible 
blockers of PI-3K, respectively. As shown in Fig. 3, both LY 294002 (10 µM, 10 – 15 
min) and wortmannin (500 nM, 8 – 15 min) fully suppressed ET-1-induced activation of 
ICl,swell. Exposure to LY 294002 (10 μM) and wortmannin (500 nM) in the continued 
presence of ET-1 decreased the outward current at +60 mV by 102 ± 7% (n = 4, P = 0.01) 
and 92 ± 3% (n = 4, P <0.001), respectively, and the currents after LY 294002 and 
wortmannin were not significantly different from the control (n = 4, P = 0.94 and n = 4, P 
= 0.58, respectively).  
3.5. ROS are Required Intermediates in the ET-1-Induced Activation of ICl,swell  
Previously we showed that ROS are required intermediates in the regulation of 
ICl,swell by stretch, osmotic swelling and several signaling molecules (Browe & 
Baumgarten, 2004; Browe & Baumgarten, 2006; Ren et al., 2008). We examined the role 
of ROS in the ET-1-induced activation of ICl,swell using ebselen, a membrane-permeant 
glutathione peroxidase mimetic that dismutates H2O2 to H2O. Figure 4 A and B shows the 
family of currents and I-V curves before and after stimulation of ICl,swell with ET-1 (10 
nM, 10 min) and after adding ebselen (15 µM, 15 min) in presence of ET-1. Fig. 4C 
shows the normalized current. Ebselen reduced the outward current at +60 mV from 1.80 
 0.36 pA/pF to 0.45  0.15 pA/pF, a block of 112.6  10.2% (n = 4, P <0.01).  
3.6. NOX is Critically Involved in the Activation of ICl,swell by ET-1 
NOX has been implicated as the source of ROS that activates ICl,swell (Browe & 
Baumgarten, 2004; Browe & Baumgarten, 2006; Ren et al., 2008). To test whether ET-1  
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Figure 4:  ROS were required intermediates in ET-1-induced activation of ICl,swell.  
(A) Families of currents before and after stimulation of ICl,swell by ET-1 (10 nM, 10 min) 
and after adding ebselen (15 µM, 15 min) in presence of ET-1.  Ebselen is a membrane-
permeant glutathione peroxidase mimetic that dismutates H2O2 to H2O. (B) IV curves for 
A.  (C) Normalized current at +60 mV from cells exposed to ebselen in continuous 
presence of ET-1.  Ebselen inhibited 112.6  10.2% (n = 4, P < 0.01) of the ET-1-
induced current.  Signaling cascade is summarized in inset. 
45 
 
 
signaling requires NOX activity, we used apocynin, a selective NOX inhibitor. Fig. 5 
shows that apocynin suppressed the current elicited by ET-1. ET-1 (10 nM, 10 min) 
increased the outward current at +60 mV from 0.43  0.08 pA/pF to 1.16  0.18 pA/pF.  
Apocynin (500 µM, 10 – 15 min) applied in continued presence of ET-1 suppressed 85.8 
 6.5% (n = 5, P <0.001) of the ET-1-induced current, and currents after block were not 
significantly different from control (n = 5, P = 0.356).   
3.7. Mitochondrial ROS are Required for the ET-1-Induced Activation of ICl,swell 
Although NOX is a required source of ROS, it remains unclear whether it is the 
only source of ROS involved in the activation of ICl,swell. An important alternative is 
mitochondria, and Complex III plays a central role in mitochondrial ROS generation 
(Chen et al., 2003). The highly selective Complex I inhibitor rotenone suppresses e– flow 
to Complex III and inhibits ROS generation by intact mitochondria (Chen et al., 2003). 
As shown in Fig. 6, application of rotenone (10 µM, 25 – 45 min) in the continued 
presence of ET-1 reduced the outward current at +60 mV from 1.90  0.16 pA/pF to 0.96 
 0.14 pA/pF (n = 4, P <0.001), which amounts to block of 84.5  4.4%, and the current 
after application of rotenone was not significantly different from control (n = 4, P = 
0.14). 
3.8. Activtaion of ICl,swell by Mitochondrial ROS is Downstream from NOX 
ET-1-induced ICl,swell was completely blocked by inhibitors of either ROS source, 
suggesting that NOX and mitochondria must act in series rather than in parallel. To verify 
that mitochondrial ROS can activate ICl,swell, we used the Complex III inhibitor antimycin 
A and the mitoKATP agonist diazoxide, which are both known to stimulate mitochondrial 
ROS production (Chen et al., 2003; Busija et al., 2005; Drose et al., 2009). 
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Figure 5:  NADPH oxidase (NOX) was critically involved in the activation of ICl,swell 
by ET-1.  (A) Families of currents before and after activation of ICl,swell by ET-1 (10 nM, 
10 min) and after application of highly selective NOX inhibitor apocynin (500 nM, 10-15 
min) in presence of ET-1.  (B) I-V relationships for (A).  (C) Current densities at +60 mV 
for activation of ICl,swell by ET-1and its block by apocynin.  Apocynin suppressed 85.8  
6.5% (n = 5, P < 0.001) of the ET-1-induced current, and currents after block were not 
significantly different than control (n = 5, P = 0.356). Signaling cascade is summarized in 
insets. 
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Figure 6:  ROS from mitochondria were required for ET-1-induced activation of 
ICl,swell.  (A) Families of currents before and after activation of ICl,swell by ET-1 (10 nM, 10 
min) and after application of the highly selective mitochondrial e– transport blocker 
rotenone (10 µM, 25-45 min) in presence of ET-1.  (B) IV relationships for (A).  (C) 
Current densities of the cells exposed to rotenone in the continued presence of ET-1.  
Rotenone inhibited 84.5  4.4% (n = 4, P <0.001) of the ET-1-induced current, and 
current after block was not significantly different than control (n = 4, P = 0.14). Signaling 
cascade is summarized in insets. 
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As expected, both antimycin A and diazoxide elicited ICl,swell (Fig. 7A, B). Antimycin A 
(10 µM, 5 – 10min) increase the outward current at +60 mV from 0.54  0.11 pA/pF to 
1.40  0.14 pA/pF (n = 9, P <0.001) and diazoxide (50 µM, 5 – 10min) from 0.60  0.13 
pA/pF to 1.78  0.47 pA/pF (n = 5, P <0.01).  
Next we tested whether production of ROS by NOX was downstream from 
mitochondrial ROS in the activation of ICl,swell. Contrary to this scheme, ICl,swell elicited by 
antimycin A and diazoxide was insensitive to two selective NOX blockers, apocynin (500 
µM, 10 – 15 min; n = 5, P = 0.69, Fig. 7A) and the fusion peptide gp91ds-tat (500 nM, 15 
– 20 min; Fig. 7A: n = 6, P = 0.14; Fig. 7B: n = 5, P = 0.92). These data and the finding 
that inhibitors of both NOX and mitochondrial ROS production (Fig. 5 and 6) fully 
suppressed ICl,swell suggest that NOX must be upstream of mitochondrial ROS production 
rather than downstream. 
3.9. ICl,swell Induced by Mitochondrial ROS is Insensitive to Osmotic Shrinkage 
Previously we showed that osmotic shrinkage suppressed the ICl,swell elicited by 
EGF but failed to inhibit activation of ICl,swell in response to H2O2, which is the most 
distal regulator of ICl,swell in the proposed signaling pathway (Ren et al., 2008). We 
examined whether osmotic shrinkage-induced signaling is upstream from mitochondrial 
ROS. Fig. 8 shows that ICl,swell induced by the complex III inhibitor antimycin A was 
insensitive to osmotic shrinkage with 1.5T bath solution. Antimycin A (10 µM, 5-10min) 
increased the outward current +60 mV from 0.53  0.11 pA/pF to 1.86  0.07 pA/pF (n = 
4, P <0.001), and the current after switching to hyperosmotic bath solution (1.5T, 15 – 25 
min) containing antimycin A was 1.92  0.13 pA/pF, which was not significantly 
different from the value before osmotic shrinkage (n = 4, P = 0.75).
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Figure 7:  Activation of ICl,swell by mitochondrial ROS was downstream from 
NADPH oxidase (NOX).  Antimycin A (A; 10 µM), an inhibitor of Complex III, and 
diazoxide (B; 50 µM), a mitoKATP agonist, are known to stimulate mitochondrial ROS 
production, and both elicited ICl,swell.  Mitochondrial ROS-induced ICl,swell was insensitive 
to two selective NOX blockers, apocynin (500 µM, 10-15 min; n = 5, P = 0.69) and the 
fusion peptide gp91ds-tat (500 nM, 15-20 min; A: n = 6, P = 0.14; B: n = 5, P = 0.92).  
Failure of apocynin and gp91ds-tat to block ICl,swell implied that mitochondrial ROS 
production must be downstream from NADPH oxidase in the signaling cascade.  
Diagrams of signaling cascades assuming mitochondria were upstream (right) or 
downstream (left) from NADPH oxidase are shown as inserts.  The cascade denoted by 
 (left) was excluded. 
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Figure 8:  ICl,swell induced by mitochondrial ROS was insensitive to osmotic 
shrinkage.  (A) Families of currents before and after activation of ICl,swell by antimycin A 
(10 µM, 5-10min) and after application of 1.5 times osmotic (1.5T) solution.  (B) IV 
relationships for A.  (C) Current densities for cells exposed to 1.5T solution in the 
continued presence of antimycin A.  Antimycin A (10 µM, 5-10min) increased the 
outward current +60 mV from 0.53  0.11 pA/pF to 1.86  0.07 pA/pF (n = 4, P <0.001), 
and the current after switching to hyperosmotic bath solution (1.5T, 15-25 min) with 
antimycin A was 1.92  0.13 pA/pF, which was not significantly different from the value 
before osmotic shrinkage (n = 4, P = 0.75). 
51 
 
 
3.10. Role of ERK in the Activation of ICl,swell Induced by ET-1, EGF, and H2O2 
ERK is involved in the activation of ICl,swell in failing heart (Clemo & 
Baumgarten, 1999) and potenitaion of ICl,swell by ET-2 (Du & Sorota, 2000). In order to 
determine the role of ERK in the signaling pathway that regulates ICl,swell, we examined 
the effect of ERK inhibitors on the current elicited by EGF, ET-1, and H2O2. As 
illustrated in Fig. 9A, EGF-induced ICl,swell was fully inhibited by the ERK1 blocker 
PD98059 and ERK1/2 blocker U0216. EGF (10 nM, 10 min) increased the outward 
current at +60 mV by 1.16  0.03 pA/pF, from 0.57  0.13 pA/pF to 1.73  0.16 pA/pF (n 
= 9, P <0.001). At +60 mV,  PD98059 (10 µM, 10 min) reduced the EGF-induced current 
by 101.4  7.0%, from 1.81  0.22 pA/pF to 0.56  0.13 pA/pF (n = 5, P <0.01) and 
U0126 (5 µM, 10 min) blocked 105.5  5.1%, reducing the current from 1.63  0.27 
pA/pF to 0.52  0.16 pA/pF (n = 4, P < 0.01). In contrast, ET-1-induced ICl,swell (10 nM, 
10 min) was partially inhibited by PD98059 and U0126 (Fig.9B).  PD98059 (10 µM, 15 
min) blocked 69.9  4.0% (n = 5, P <0.05) and U0216 (5 µM, 15 min) inhibited 68.6  
7.4% (n = 5, P <0.01) of ET-1-induced current. Although these concentrations of 
PD98059 and U0126 were sufficient to fully suppress ICl,swell elicited by EGF, it was 
important to verify their potency in response to ET-1. Increasing the concentration of 
PD98059 from 10 to 30 µM and U0216 from 5 to 10 µM in the same cells did not result 
in additional block (Fig. 9B). As shown in Fig.9C, exogenous H2O2 (100 µM, 5 min) 
induced activation of ICl,swell, and PD98059 (10 µM, 15 min) had no effect on the H2O2-
induced current (n = 4, P = 0.57). 
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Figure 9:  ERK-dependent and ERK-independent activation of ICl,swell by ET-1, EGF 
and H2O2.  (A) EGF-induced ICl,swell (10 nM, 10 min) was fully inhibited by the ERK1 
blocker PD98059 (10 µM, 15 min; 101.4  7.0%, n = 5, P < 0.01) and the ERK1/2 
blocker U0126 (5 µM, 10 min; 105.5  5.1%, n = 4, P < 0.01).  (B) By contrast, ET-1-
induced ICl,swell (10 nM, 10 min) was partially inhibited by ERK blockers.  PD98059 (10 
µM) blocked 69.9  4.0% of ET-1-induced ICl,swell (n = 5, P < 0.02 ); increasing PD98059 
to 30 µM in 2 of these cells had no additional effect.  Similarly, U0126 (5 µM) blocked 
68.6  7.4% (n = 5, P < 0.02), and increasing U0126 to 10 µM (n = 5) in the same cells 
had no additional effect.  (C) H2O2 (100 µM, 5 min) elicits ICl,swell at a site distal to ERK 
and was unaffected by PD98059 (n = 4, P = 0.57). 
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3.11. AngII Elicited ICl,swell via ETA Receptors   
The results described so far indicate that activation of ICl,swell by ET-1 involve 
some of the same signaling molecules that are involved in the activation of ICl,swell by 
AngII (Browe & Baumgarten, 2004; Browe & Baumgarten, 2006; Ren et al., 2008).  This 
raises a question:  Are ET-1 and AngII part of a single signaling cascade or do they 
represent two independent signaling pathways that converge? If AngII and ET-1 act in 
series, block of one should suppress activation by the other peptide. Consistent with a 
series arrangement with ET-1 downstream from AngII, Fig.10 A shows that activation of 
ICl,swell by AngII (5 nM, 5 – 10 min) was completely abolished by ETA receptor blockade. 
Application of AngII (5 nM, 5 – 10 min) increased the outward current at +60mV from 
0.40 ± 0.02 pA/pF to 1.38 ± 0.24 pA/pF and selective ETA receptor blocker BQ123 (1 
µM, 5 – 10 min) blocked 92 ± 3% (n = 5, P < 0.01) of AngII-induced current. In contrast, 
the AT1R blocker losartan (5 µM, 15 min) did not alter ET-1-induced ICl,swell (n = 4, P = 
0.92) (Fig.10 B).   
3.12. Osmotic Swelling Elicited ICl,swell via ETA Eeceptors   
Previously we showed that osmotic swelling activates ICl,swell via AngII AT1 
signaling (Ren et al., 2008). This and our observation that ET-1 ETA receptor is 
downstream from AngII in the cascade regulating ICl,swell imply that the response to 
osmotic swelling also should be suppressed by an ETA inhibitor. Confirming this idea, 
Fig. 10 C shows that BQ123 inhibited the activation of ICl,swell in response to osmotic 
swelling. Osmotic swelling (0.7T, 10 min) induced the outward current at +60mV from 
0.67 ± 0.16 pA/pF to 1.80 ± 0.42 pA/pF and application of the selective ETA receptor 
blocker BQ123 (1 µM, 5 – 10 min) in 0.7T solution blocked 91 ± 4% of osmotic 
swelling-induced current (n = 4, P <0.01). 
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Figure 10:  AngII and osmotic swelling (0.7T) elicited ICl,swell via ETA receptors.  (A) 
Activation of ICl,swell by AngII (5 nM, 5-10 min) was suppressed (92.0 ± 3.2%; n = 5, P < 
0.01) by the ETA blocker BQ123(1 µM, 5 – 10 min).  (B) Confirming AT1 was upstream 
from ETA, the AT1 blocker losartan (5 µM, 15 min) did not alter ET-1-induced ICl,swell (n 
= 4, P = 0.92).  (C) ICl,swell elicited by osmotic swelling (0.7T, 5 min) was abolished (91 ± 
4%; n = 4, P < 0.01) by BQ123 (1 µM, 5 – 10 min).  Signaling schemes are shown in 
inserts. The cascade denoted by  (middle) was excluded. 
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Chapter 4 
RESULTS IN CULTURED MOUSE HL-1 ATRIAL CELLS 
 
 
Immortalized HL-1 murine atrial myocytes share a number of phenotypic 
properties with adult atrial myocytes and recently have emerged as a useful alternative 
for studying cardiac physiology and pathophysiology (Claycomb et al., 1998; White et 
al., 2004). Although several cation channels have been described in HL-1 cells, the 
presence and behavior of Cl channels has not been considered. This chapter documents 
the presence and regulation of ICl,swell in HL-1 cells and makes use of this cell line to 
study ET-1-induced ROS production by flow cytometry.  
4.1. ICl,swell is Present in the Mouse Atrial HL-1 Cells 
The effect of osmotic swelling in HL-1 myocytes was studied in 0.85T rather than 
0.7T hypoosmotic bath solution because exposure to 0.7T rapidly caused all the cells in 
the chamber to rupture. Despite applying a more modest osmotic challenge than was used 
with adult myocytes, 0.85T (5 – 10 min) elicited a robust outwardly rectifying current in 
HL-1 cells. With a physiologic Cl gradient, osmotic swelling increased the outward 
current at +60 mV from 4.20  0.93 pA/pF to 30.69  2.75 pA/pF (n = 7, P <0.001), and 
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the selective ICl,swell inhibitor DCPIB blocked 110.5  11.2% (n = 6, P <0.001) of the 
swelling-induced current (Fig 11).   
To verify that the outwardly rectifying current was ICl,swell, we also studied it with 
a symmetrical Cl- gradient.  ICl,swell undergoes outward rectification in both physiological 
and symmetrical Cl, whereas a number of other Cl currents are linear under 
symmetrical conditions (Hume et al., 2000).  As expected for ICl,swell, Fig. 12 shows that 
the current elicited by osmotic swelling in symmetrical Cl remained outwardly 
rectifying. Swelling increased the current at +60 mV from 0.45  0.18 pA/pF to 12.19  
0.58 pA/pF (n = 4, P <0.001), and DCPIB blocked 100.9  2.9% (n = 4, P <0.001).   
4.2. Exogenous H2O2 Elicits ICl,swell in HL-1 Cells 
Another characteristic of ICl,swell in adult myocytes is its activation by H2O2 
(Browe & Baumgarten, 2004). Exogenous H2O2 also induced an outwardly rectifying Cl- 
current that was sensitive to DCPIB in HL-1 cells (Fig. 13). H2O2 (100µM, 5-10min) 
increased the outward current at +60 mV from 2.70  1.23 to 24.18  4.40 pA/pF (n = 6, 
P <0.001), and DCIPB blocked 101.3  12.6% (n = 4, P <0.001) of the H2O2-induced 
current. 
4.3. NOX Regulates Swelling-Induced ICl,swell in HL-1 Cells 
Next we studied whether ROS were involved in the activation of ICl,swell in HL-1 
cells upon osmotic swelling and identified the source of ROS. Previous studies showed 
that the selective NOX inhibitor apocynin fully inhibited the osmotic swelling-induced 
ICl,swell in rabbit ventricular cardiomyocytes (Ren et al., 2008), and we showed (Fig. 5)  
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Figure 11: Osmotic swelling activated a DCPIB-sensitive outwardly rectifying Cl– 
current in HL-1 cells with physiological Cl– gradient.  (A) Families of currents before 
and after exposure to 0.85T solution (5-10 min) and after addition of DCPIB (10 μM, 5-
10 min) in the presence of 0.85T solution.  (B) I-V relationships for A.  Cell capacitance 
was 24.8 pF.  (C) Normalized current for cells exposed to DCPIB in 0.85 T solution.  
DCPIB blocked 110.5  11.2% of swelling-induced current (n = 6, P <0.001).  
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Figure 12:  Osmotic swelling induced an outwardly rectifying Cl- current in HL-1 
cells with symmetrical Cl- gradient.  (A) Families of currents before and after exposure 
to 0.85T bath solution (5-10 min) and after addition of DCPIB (10 μM, 5-10 min) in the 
0.85T bath solution.  (B) I-V relationships for A.  Cell capacitance was 76.5 pF.  (C) 
Normalized current for cells that were exposed to DCPIB in 0.85 T bath solution.  
DCPIB blocked 100.9  2.9% of swelling-induced current (n = 4, P <0.001).  
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Figure 13:  H2O2 activated ICl,swell in HL-1 cells.  H2O2 elicited an outwardly 
rectifying Cl- current that was blocked by DCPIB.  (A) Families of currents before and 
after exposure to H2O2 (100 μM, 5-10 min) and after addition of DCPIB (10 μM, 5-10 
min) in the presence of 0.85T solution.  (B) I-V relationships for A.  Cell capacitance was 
39.0 pF.  (C) Normalized current for cells exposed to DCPIB in continued presence of 
H2O2.  H2O2 (100µM, 5-10min) increased the outward current at +60 mV from 2.70  
1.23 to 24.18  4.40 pA/pF (n = 6, P <0.001), and DCIPB blocked 101.3  12.6% (n = 4, 
P <0.001) of H2O2-induced current. 
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that it also blocked ICl,swell in rabbit atrial myocytes. However, as shown in Fig. 14, 
apocynin (500µM, 15min) failed to inhibit the activation of ICl,swell in response to osmotic 
swelling in HL-1 cells (n = 5, P = 0.82). Apocynin is a pro-drug that must be activated by 
myeloperoxidase (Heumuller et al., 2008).  This raised the possibility the insensitivity to 
apocynin reflected a failure to activate the pro-drug rather than a lack of involvement of 
NOX, and therefore, we tested another selective NOX inhibitor, the fusion peptide 
gp91ds-tat. By contrast to apocynin, gp91ds-tat completely inhibited osmotic swelling-
induced ICl,swell in HL-1 cells (Fig. 15). After swelling increased the current at +60 mV 
from 1.99  0.62 pA/pF to 14.52  2.54 pA/pF, addition of gp91ds-tat (500 nM, 10 – 15 
min) in 0.85T solution blocked 103.1  3.3% of the swelling-induced current (n = 4, P 
<0.001).  
4.4. Mitochondrial ROS Regulate ICl,swell in HL-1 Cells  
Mitochondrial ROS is critically involved in the regulation of ICl,swell in rabbit atrial 
myocytes (Fig. 6). We examined whether mitochondrial ROS also regulates ICl,swell in 
HL-1 cells. Swelling-induced ICl,swell in HL-1 cells was fully inhibited by the Complex I 
blocker rotenone (Fig.16). Application of rotenone (10 µM, 15 – 30 min) in 0.85T 
solution reduced the outward current at +60 mV from 15.95  3.3 pA/pF to 0.97  0.18 
pA/pF. The osmotic swelling-induced current in HL-1 cells was inhibited 110.8  9.6% 
(n = 5, P <0.001) by rotenone and the current after application of rotenone was not 
significantly different from control (n = 5, P = 0.72).  
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Figure 14:  Apocynin failed to block ICl,swell in HL-1 cells.  (A) Families of currents 
before and after exposure to 0.85T solution (5-10 min) and after addition of apocynin 
(500µM, 15min) and DCPIB (10 μM, 5-10 min) in the presence of 0.85T solution.  (B) I-
V relationships for A.  Cell capacitance was 39.9 pF.  (C) Normalized current for cells 
exposed to apocynin and DCPIB in 0.85 T solution.  Apocynin (500µM, 15min) had no 
effect on the activation of ICl,swell in response to osmotic swelling in HL-1 cells (n = 5, P 
= 0.82).  In contrast, DCPIB (10 μM, 5-10 min) blocked 106.0  4.4% of swelling-
induced current of the same cells (n = 4, P <0.001).  
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Figure 15:  Gp91ds-tat inhibited activation of ICl,swell by osmotic swelling in HL-1 
cells.  (A) Families of currents before and after exposure to 0.85T solution (5-10 min) and 
after application of gp91ds-tat (500 nM, 10-15 min) in 0.85T solution.  Gp91ds-tat is a 
fusion peptide that specifically blocks the docking site of p47phox.  (B) I-V relationships 
for A.  Cell capacitance was 38.7 pF.  (C) Normalized current from cells exposed to 
gp91ds-tat in 0.85 T solution.  Gp91ds-tat (500 nM, 10-15 min) blocked 103.1  3.3% of 
swelling-induced current (n = 4, P <0.001).  
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Figure 16:  Rotenone inhibited swelling-induced ICl,swell in HL-1 cells.  (A) Families of 
currents before and after exposure to 0.85T solution (5-10 min) and after application of 
rotenone (10 µM, 15-30 min) in 0.85T solution.  (B) I-V relationships for A.  Cell 
capacitance was 38.0 pF.  (C) Normalize d current from cells exposed to rotenone in 0.85 
T solution.  Rotenone (10 µM, 15-30 min) blocked 110.8  9.6% (n = 5, P <0.001) of 
swelling-induced current (n = 5, P <0.001).  
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4.5 ET-1 Induces ICl,swell in HL-1 Cells  
 
Fig. 17 and 18 show that exposure to ET-1 induced an outwardly rectifying Cl– 
current that is blocked by DCPIB in HL-1 cells in both physiological and symmetrical Cl–
. ET-1 (10 nM, 5-10 min) increased the outward current at +60 mV from 0.99  0.38 
pA/pF to 27.79  2.00 pA/pF (n = 5, P <0.001) in physiological Cl– and from 0.92  0.40 
pA/pF to 16.78  4.01pA/pF (n = 4, P <0.001) in symmetrical Cl–. DCPIB blocked 100.2 
 0.35% (n = 4, P <0.001) and 100.4  0.88% (n = 4, P <0.001) of swelling-induced 
current in physiological and symmetrical Cl–, respectively.  
4.6 ET-1 Induces ICl,swell in HL-1 Cells via ETA Receptors 
Selective ETA blocker BQ123 suppressed ET-1-1induced ICl,swell in HL-1 cells 
(Fig. 19). ET-1 (10 nM, 5-10 min) increased the current at +60 mV from 0.79 ± 0.28 to 
36.62 ± 5.68 pA/pF, and application of BQ 123 (10 µM, 10 min) with continuous 
presence of ET-1 reduced the current to 0.55 ± 0.06 pA/pF, a block of 101.3 ± 1.4% (n = 
4, P <0.001). Current after application of BQ123 was not significantly different from the 
control (n = 4, P = 0.96). 
4.7 NOX is Essential for ET-1-Induced ICl,swell in HL-1 Cells 
ET-1-induced ICl,swell was blocked by the specific NOX inhibitor gp91ds-tat in 
HL-1 cells (Fig.20). At+60 mV, ET-1 increased the current by 36.53  5.98 pA/pF, from 
1.46  0.82 to 37.09  6.80 pA/pF, and gp91ds-tat (500 nM, 10-15 min) applied in 
continued presence of ET-1 decreased the outward current to 1.79  0.88 pA/pF. The 
NOX blocker gp91ds-tat suppressed 98.6 0.9% (n = 4, P <0.01) of the ET-1-induced  
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Figure 17:  ET-1 activated a DCPIB-sensitive outwardly rectifying Cl- current in 
HL-1 cells with physiological Cl- gradient.  (A) Families of currents before and after 
exposure to ET-1 (10 nM, 10 min) and after addition of DCPIB (10 μM, 5-10 min) in the 
presence of ET-1.  (B) I-V relationships for A.  Cell capacitance was 47.2 pF.  (C) 
Normalized current for cells exposed to DCPIB solution in continuous presence of ET-1.  
DCPIB blocked 100.2  0.35% (n = 4, P <0.001) of the current elicited by ET-1.  
 
66 
 
 
 
 
 
 
 
 
Figure 18:  ET-1 induced an outwardly rectifying Cl- current that was sensitive to 
DCPIB in HL-1 cells with symmetrical Cl- gradient.  (A) Families of currents before 
and after exposure to ET-1 (10 nM, 10 min) and after addition of DCPIB (10 μM, 5-10 
min) in the presence of ET-1.  (B) I-V relationships for A.  Cell capacitance was 81.6 pF.  
(C) Normalized current from cells exposed to DCPIB solution in continuous presence of 
ET-1.  DCPIB blocked and 100.4  0.88% (n = 4, P <0.001) of the ET-1-indued current.  
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Figure 19:  ET-1 activated ICl,swell  in HL-1 cells via ETA receptors.  (A) Families of 
currents before and after exposure to ET-1 (10 nM, 10 min) and after addition of BQ 123 
(10 µM, 10 min) in the presence of ET-1.  (B) I-V relationships for A.  Cell capacitance 
was 49.4 pF.  (C) Normalized current for cells exposed to BQ123 in continuous presence 
of ET-1.  ET-1 blocked 101.3 ± 1.4% (n = 4, P <0.001) of the current elicited by ET-1.  
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Figure 20:  NOX was involved in the activation of ICl,swell  by ET-1 in HL-1 cells.  (A) 
Families of currents before and after exposure to ET-1 (10 nM, 10 min) and after addition 
of gp91ds-tat (500 nM, 10-15 min) in the presence of ET-1.  (B) I-V relationships for A.  
Cell capacitance was 46.8 pF.  (C) Normalized current for cells exposed to gp91ds-tat in 
continuous presence of ET-1. Gp91ds-tat suppressed 98.6  0.9% (n = 4, P <0.01) of the 
ET-1-induced current.  
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current, and currents after block were not significantly different from control (n = 4, P = 
0.96).   
4.8.Measurement of ROS Production by Flow Cytometry 
Fig. 21 shows the representative gated log fluorescence histograms from a typical 
experiment.  ET-1 itself is not fluorescent, as no increase in fluorescence was observed 
after treatment of HL-1 cells with ET-1 (10 nM, 20 min) in the absence of C-H2DCFDA-
AM (Fig. 21 A).  By contrast, ET-1 increased fluorescence above background levels in 
C-H2DCFDA-AM-loaded cells, which indicates that ET-1 enhanced ROS production 
(Fig.21 B). Pretreatment with rotenone (10µM) or gp91ds-tat (500 nM) for 1 hr prevented 
ET-1-induced C-H2DCFDA-AM fluorescence suggesting that both NOX and 
mitochondrial ROS production were involved (Fig.21 C).  Summary data based on the 
geometric means of the fluorescence distributions are shown in Fig. 22 and confirmed the 
interpretation of the electrophysiologic data.  ET-1 significantly increased ROS 
production as compared to that under background conditions, and ROS production was 
statistically unchanged from background after either rotenone or gp91ds-tat pretreatment.   
The increase of C-H2DCFDA-AM fluorescence by ET-1 followed an exponential 
time course, and the steay state was reached at ~20 min (Fig. 23). The time couse data 
were fitted individually to an exponential function f=a*(1-exp(-1/*x)) where a is the 
amplitude of C-H2DCFDA-AM fluorescence and  is the time constant. The mean 
amplitude was 6.2  0.7 and  was 12.2  1.7 min.  
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Figure 21: Gated log fluorescence (F) histograms from a typical experiment showing 
that ET-1-induced ROS production was abrogated by gp91ds-tat and rotenone. 
Intracelluar ROS was detected with C-H2DCFDA-AM, which is converted into a non-
fluorescent derivative (carboxy-H2DCF) by intracellular esterases. Carboxy-H2DCF is 
retained in the cytoplasm and is oxidized to fluorescent carboxy-DCF by intracellular 
ROS. The numbers represent the geometric mean of the fluorescence density.  (A) 
Negative control (without loading the cells with C-H2DCFDA-AM) in the presence and 
absense of ET-1.  ET-1 itself was not fluorescent.  (B) Cells loaded with C-H2DCFDA-
AM (2.5 µM) and treated with ET-1 (10 nM, 10min or 40min) or, as a positive control, 
H2O2 (100µM, 10 min). ET-1 and H2O2 increased fluorescence. (C) C-H2DCFDA-AM-
loaded cells that were pretreated with rotenone (10 µM) or gp91ds-tat (500 nM) for 1 hr 
before stimulation with ET-1 (10 nM, 20 min).  Consistent with the patch clamp data, 
both rotenone and gp91ds-tat fully suppressed ET-1-induced ROS production. 
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Figure 22:  ET-1-induced the C-H2DCFDA-AM fluorescence was abrogated by 
rotenone and gp91ds-tat. ET-1 (10 nM, 20 min) and H2O2 (100 M, 10 min) 
significantly increased fluorescence above background, and after pretreatment (1 hr) with 
rotenone (10 µM) or gp91ds-tat (500 nM), the ET-1-induced fluorescence was not 
significantly different than control (n = 4 – 10, P < 0.05).  The response to H2O2 served 
as a positive control.  For each experiment, the geometric mean fluorescence after an 
experimental intervention was calculated as the fold-increase relative to background 
fluorescence (FL/FLO). Because the summary data sets were not normally distributed, 
Kruskal-Wallis One Way ANOVA on Ranks was applied, and pairwise comparisons 
were made by Dunn's method; 25%, 50%, and 75% percentiles are denoted in box plots, 
and error bars represent 10% and 90% percentiles. 
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Figure 23: Time course of the C-H2DCFDA-AM fluorescence induced by ET-1. ET-1 
induced florescence is ploted as fold-increase relative to background fluorescence 
(FL/FLO).  The data were fitted individually to a sigmoidal function,  f  =  1 + a/(1 + exp 
(-(x-x0)/b)), where a is the amplitude of C-H2DCFDA-AM fluorescence, x0 is the half 
time for activation, and b is the slope factor.  The mean amplitude of FL/FLO was 5.1  
0.6, x0 was 9.5  1.3, and b was 7.1  1.8 (solid line).  **, significant differences from 
background at t = 0 (n = 5; P < 0.01).  Time-course data were assessed with a repeated 
measures ANOVA and compared to control (t = 0) by the Holm-Sidak method.  Symbols 
and error bars are mean  SEM. 
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 Flow cytometry also was used to confirm that antimycin A activated 
mitochondrial ROS production independent of effects on NADPH oxidase.  Antimycin A 
(20 M, 20 min) significantly increased ROS production 3.6-fold relative to background 
(n = 3, P < 0.05).  Pretreatment with rotenone (10 µM, 20 min) reduced antimycin A-
induced ROS production to 1.2-fold above background (n = 2, ns), whereas after 
pretreatment with gp91ds-tat (500 nM, 20 min) antimycin A-induced ROS production 
remained elevated by 3.5-fold (n = 2, P < 0.05).  
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Chapter 5 
DISCUSSION 
 
 
5.1. ET-1 Activates an Outwardly Rectifying Cl– Current with Properties of ICl,swell in 
Atrial Myocytes. 
 The primary Cl– channels expressed by atrial myocytes include ICl,cAMP, ICl,Ca, and 
ICl,swell (for review, see Hume et al., 2000).  In the present study, we showed that ET-1 
activated an outwardly rectifying Cl– current with properties of ICl,swell rather than either 
ICl,cAMP or ICl,Ca.  First, the ET-1-induced Cl– current was blocked by highly selective 
ICl,swell blocker DCPIB. Both ICl,cAMP and ICl,Ca are insensitive to DCPIB (Decher et al., 
2001). Second, the ET-1-induced was suppressed by osmotic shrinkage.  Volume 
sensitivity is an important feature of ICl,swell that distinguishes it from ICl,PKA and ICl,Ca 
(Hume et al., 2000). Finally, the ET-1-induced Cl– current is outward rectifying with 
symmetrical Cl– gradient, which is a fundamental characteristic of ICl,swell (Hume et al., 
2000; Baumgarten & Clemo, 2003). In contrast, ICl,PKA and ICl,Ca are linear in symmetrical 
Cl– (Hume et al., 2000).  
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 Du and Sorota  (2000) reported that ET-1 potentiates ICl,swell after it is tuned on by 
hydrostatic positive-induced cell inflation.  However, the effect of ET-1 on ICl,swell 
without pre-activation by cell inflation or osmotic swelling was not investigated in the 
study.  The present study showed that ET-1 elicits ICl,swell under isomotic conditions 
without cell inflation, which argues for a role of ET-1 as an activator of ICl,swell.  
5.2. ET-1 Activates ICl,swell via ETA but not ETB Receptors 
 ET-1 interacts with two receptor subtypes, ETA and ETB. Both ETA and ETB 
receptors are expressed in the atrial myocytes, although ETA is the predominant isoform 
(Russell & Molenaar, 2000). ET-1-induced myocardial hypertrophy, fibrosis, 
inflammation, and arrhythmogenic effects are generally linked to ETA receptors (Chen et 
al., 2001; Rothermund et al., 2002; Fraccarollo et al., 2002), but other studies suggest 
that ETB receptors may also play a role (Hocher et al., 1999; Burrell et al., 2000; Cullen 
et al., 2001; Lee et al., 2004; Yang et al., 2004).  
 Previously we showed that ROS are required intermediates for the activation of 
ICl,swell ventricular cardiomyocytes (Browe & Baumgarten, 2004; Ren et al., 2008). ETA 
receptors were shown to be responsible for ET-1-induced ROS production in VSMCs 
(Laplante et al., 2005) and cardiomyocytes (Cingolani et al., 2006). However, in human 
umbilical vein endothelial cells ET-1-induced ROS generation was attributed to ETB 
receptors (Dong et al., 2005). In agreement with previous studies, we showed that 
selective ETA receptor blockade abolished the activation of ICl,swell induced by ET-1 in 
atrial myocytes, whereas an ETB receptor blocker had no effect. ETB receptors are the 
predominant ET receptor subtypes expressed in the endothelial cells (Winkles et al., 
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1993), and it is likely that there are tissue-specific differences in the linkage bet          
ween ROS production and the ET receptor subtypes.   
5.3. Transactivation of EGFR kinase and its Potential Role in the ET-1-Induced 
Activation of ICl,swell 
 EGFR kinase is an important member of the ErbB family of receptor tyrosine 
kinases. It dimerizes and trans-autophosphorylates six specific tyrosines within its 
cytoplasmic tail upon ligand binding (Prenzel et al., 1999; Anderson et al., 2004). We 
previously showed that EGFR kinase blockade fully inhibited the activation of ICl,swell by 
β1-integrin stretch and osmotic swelling, and exogenous EGF elicited ICl,swell under 
isosmotic conditions in ventricular myocytes (Browe & Baumgarten, 2006; Ren et al., 
2008). EGF also has been shown to participate in the regulation of ICl,swell in other cell 
types including C127 mammary cells (Abdullaev et al., 2003) and liver-derived HTC 
cells (Varela et al., 2004). The present study provides the first evidence that EGFR kinase 
mediates the activation of ICl,swell by ET-1. First, ET-1 induced activation of ICl,swell was 
fully inhibited by selective EGFR kinase blocker AG1478, which inhibits ATP binding to 
EGFR kinase. Second, in agreement with the studies in the ventricular cardiomyocytes 
(Browe & Baumgarten, 2006), exogenous EGF elicited an outwardly rectifying Cl− 
current with properties of ICl,swell under isosmotic condition in atrial cardiomyocytes.  
 Transactivation of EGFR kinase by ET-1 involves the cleavage of membrane-
tethered pro-heparin-binding EGF-like growth factor (proHB-EGF) by matrix 
metalloproteinases (MMPs) and shedding of soluble heparin-binding EGF (HB-EGF), 
which binds to and activates EGFR kianse (Prenzel et al., 1999). We did not test the 
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importance of MMP dependent proHB-EGF cleavage in the activation of ICl,swell by ET-1.  
One would predict, however, that MMP inhibitors would suppress ICl,swell, and that this 
may be an unexpected consequence of their application for other purposes.  
5.4. PI-3K Regulates ET-1-Induced ICl,swell 
 PI-3K is activated by mechanical stretch (Petroff et al., 2001), integrin clustering 
(Franchini et al., 2000), osmotic swelling (Bewick et al., 1999), AngII (Rabkin et al., 
1997), EGFR kinase (Krieg et al., 2004) and ET-1 (Foschi et al., 1997; Araki et al., 2000; 
Pham et al., 2001; Shi-Wen et al., 2004). Previous studies showed that inhibition of PI-
3K suppressed the activation of ICl,swell in response to β1-integrin stretch (Browe & 
Baumgarten, 2006), osmotic swelling (Feranchak et al., 1999; Shi et al., 2002; Wang et 
al., 2004; Ren & Baumgarten, 2005), AngII (Ren et al., 2008), and EGF (Browe & 
Baumgarten, 2006).  The role of PI-3K in the activation of ICl,swell by ET-1 was supported 
by the observation that two structurally different PI-3K blockers, wortmannin and LY 
294002, fully inhibited ET-1-induced ICl,swell. 
 PI-3K has been shown to participate in the activation of NOX and generation of 
ROS in response to diverse stimuli in various tissues (Hawkins et al., 2007). There are 
several mechanisms by which PI-3K regulates NOX assembly and activation.  First, PI-
3K leads to phosphorylation of the p47phox subunit and the PI-3K products, 
PtdIns(3,4,5)P3 and PtdIns(3,4)P2, bind to the PX domains of  p47phox and direct it to the 
plasma membrane (Zhan et al., 2002; Hoyal et al., 2003). Second, PI-3K and its products 
stimulate Rac, which also is essential for NOX assembly (Park et al., 2004). Moreover, 
H2O2 generated by NADPH oxidase feeds forward to potentiate RTK – PI-3K signaling 
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and HB-EGF-induced EGFR kinase phosphorylation (Bae et al., 1997; Rhee et al., 2000; 
Frank & Eguchi, 2003; Rhee et al., 2003) 
 Wortmannin and LY294002 inhibited PI-3K by different mechanisms. 
Wortmannin covalently modifies the p110 catalytic subunit of PI-3K, whereas LY294002 
competes with ATP for the p110 active site. Previously we showed that β1 integrin 
stretch- and osmotic-induced ICl,swell were completely inhibited by LY294002 but only 
partially suppressed by 500 nM wortmannin (Browe & Baumgarten, 2006; Ren et al., 
2008). In present study, ET-1-induced ICl,swell was completely abolished by wortmannin. 
The reason for this discrepancy was not investigated. One possibility is that activation of 
ICl,swell by β1 integrin stretch and osmotic swelling involve monomeric class II PI-3K-
C2α, which is more resistant to wortmannin (IC50 = 400 nM) than dimeric PI-3K (IC50 = 
1−10 nM) (Oudit et al., 2004).  
5.5. ROS are Essential for the ET-1-Induced Activation of ICl,swell 
 H2O2 is a membrane permeant, longer-lived ROS that interacts with a large 
number of signaling molecules and ion channels (for review, see Lambeth, 2004).  We 
and others showed that ICl,swell is elicited  by exogenous H2O2 in rabbit ventricular 
myocytes (Browe & Baumgarten, 2004), HeLa cells (Varela et al., 2004) and HTC cells 
(Shimizu et al., 2004). Decomposing H2O2 with catalase inhibited the activation of ICl,swell 
in response to β1 integrin stretch and osmotic swelling (Browe & Baumgarten, 2004; Ren 
et al., 2008). Consistent with previous studies, scavenging H2O2 using ebselen abrogated 
ICl,swell induced by ET-1. Besides H2O2, ebselen also reacts with peroxynitrite as well as 
hydroperoxides including membrane-bound phospholipid and cholesterylester 
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hydroperoxidese (Schewe, 1995). Although ICl,swell was activated by exogenous H2O2, we 
cannot exclude the possibility that other ROS are also involved in the regulation of 
ICl,swell.  
 The underlying mechanism by which H2O2 regulates ICl,swell remains to be 
understood. Our data indicates that H2O2 must act at a site distal in the signaling cascade 
because H2O2-induced activation is not reversed by osmotic shrinkage with 1.5T bath 
solution (Ren et al., 2008), whereas activation by ET-1 was abrogated by osmotic 
shrinkage (Fig. 1). H2O2 may directly modify ion channels and alter their activities or 
influence the redox-sensitive signaling pathways that regulate the ion channels (for 
review, see Zima & Blatter, 2006). A recent study indicated that activation of PLCγ and 
subsequent intracellular Ca2+ mobilization mediate H2O2-induced ICl,swell in HTC cells, 
suggesting that H2O2 operates via redox-sensitive signaling pathways (Varela et al., 
2007).  However, the Ca2+-dependent mechanism is difficult to explain the activation of 
ICl,swell by H2O2 under present conditions, because the bathing solution was Ca2+ free and 
cytoplasmic free Ca2+ was clamped to ~35 nM with EGTA.  Moreover, a number of 
studies found that ICl,swell is independent of cytoplasmic Ca2+ but is inhibited by store-
operated calcium entry (SOCE) following endoplasmic reticulum (ER) calcium store 
depletion (Lemonnier et al., 2002; Zholos et al., 2005).  We can not exclude the 
possibility that H2O2 regulates ICl,swell via redox-sensitive signaling pathways in 
cardiomyocytes. Another possible mechanism is that H2O2 modified the channel itself. 
Because the molecular identity of the channel is still unclear, how the direct modification 
by ROS affects the properties of ICl,swell remains to be further studied.  
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5.6. ROS derived from NOX are Required for the Activation of ICl,swell by ET-1. 
 NOX transfers e– from intracellular NADPH to extracellular O2 and produces 
O2−, which readily undergoes dismutation to H2O2 spontaneously or by extracellular 
superoxide dismutase (SOD) (Bedard & Krause, 2007).  Previous studies showed that 
blockade of NOX inhibited the activation of ICl,swell by β1 integrin stretch, osmotic 
swelling, and AngII in cardiomyocytes (Browe & Baumgarten, 2004; Ren et al., 2008). 
Additionally, expression of the dominant negative p47S379A NOX subunit suppresses 
osmotic swelling-induced ICl,swell in HeLa cells (Varela et al., 2004), and  the non-
selective flavin-inhibitor DPI inhibited ICl,swell in both HeLa and HTC cells (Varela et al., 
2004; Shimizu et al., 2004). 
 ET-1 activates NOX in multiple cell types including cardiomyocytes (De Giusti et 
al., 2008), VSMCs (Fei et al., 2000; Li et al., 2003; Amiri et al., 2004) and endothelial 
cells (Duerrschmidt et al., 2000; Dong et al., 2005). In support of the role of NOX in the 
activation of ICl,swell by ET-1, we showed that ET-1-induced ICl,swell was blocked by 
selective NOX inhibitor apocynin, which prevents NOX assembly by conjugating thiol 
residues, and the specific NOX inhibitor gp91ds-tat blocked ET-1-induced ROS 
generation in HL-1 myocytes.   
 Both NOX2 (gp91phox ) and NOX4 are expressed in cardiac tissue (Cave et al., 
2006). In the present study we did not distinguish which isoform is responsible for the 
activation of ICl,swell  by ET-1, but the involvement of NOX2 is favored. First, it has been 
shown that NOX2 rather than NOX4 mediates AngII-induced O2− production in 
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cardiomyocytes (Bendall et al., 2002), and AngII-induced ROS production was shown to 
be mediated by ET-1 ETA signaling (Cingolani et al., 2006).  Second, the selective NOX 
inhibitor gp91ds-tat, the fusion peptide that blocks the docking site of the p47phox subunit 
of NOX, abrogate ET-1-induced ROS production in HL-1 cells.  Because NOX4 activity 
does not depend on cytoplasmic subunits including p47phox and its homologues (Bedard & 
Krause, 2007), the activity of NOX4 should not be suppressed by gp91ds-tat.   
5.7. Mitochondrial ROS are Essential for the Activation of ICl,swell by ET-1. 
 Besides NOX, another important ROS generating system in cardiomyocytes is 
mitochondria, and our preliminary data suggest that mitochondrial ROS are involved in 
the regulation of ICl,swell by ACh, ceramide, and HIV protease inhibitors (Browe & 
Baumgarten, 2007; Deng et al., 2009; Raucci, Jr. & Baumgarten, 2009). Complex I and 
Complex III are two redox centers that leak single e to molecular O2 to generate O2− 
(Chen et al., 2003; Turrens, 2003).  O2− generated by Complex I is exclusively released 
into the matrix of intact mitochondria and degraded by the matrix anti-oxidant system 
(Muller et al., 2004).  In contrast, Complex III releases O2− to both sides of the 
mitochondrial inner membrane and plays a central role in the production of ROS by 
mitochondria (Chen et al., 2003; Turrens, 2003; Muller et al., 2004). A mitochondrial 
source of ROS has been implicated ET-1 signaling in VSMCs (Touyz et al., 2004; 
Callera et al., 2006) and cardiomyocytes (Caldiz et al., 2007).   
 The role of mitochondrial ROS in the activation of ICl,swell by ET-1 was supported 
by the findings that selective Complex I inhibitor rotenone, which inhibits mitochondrial 
ROS generation by limiting the e to Complex III, completely blocked the ET-1-induced 
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ICl,swell. Moreover, pretreatment by rotenone prevented the ET-1-induced ROS production 
in HL-1 cells.  
5.8. Proposed Direction of the Crosstalk Be tween NOX and Mitoch ondria: Activation 
of ICl,swell by Mitochondrial ROS is Downstream from NOX 
 
 The crosstalk between NOX and mitochondria has been suggested in several 
recent studies. AngII, which is a well-known activator of NOX, induces mitochondrial 
ROS production in VSMCs (Kimura et al., 2005a). Either inhibition of NOX or blockade 
of mitochondrial ROS production by blocking mitoKATP channel abrogated multiple 
AngII-induced effects, including ROS production, the slow force response, 
preconditioning, lipid peroxidation, and apoptosis (Kimura et al. , 2005b; Caldiz et al. , 
2007). A recent study also showed that NOX inhibitor or mitochondrial KATP channel 
inhibitors abolished ET-1-induced ROS production and inotropic effect (De Giusti et al., 
2008). The present study suggests that ROS from both NOX and mitochondria are 
involved in the activation of ICl,swell. This raises a question: How are these sources of ROS 
arranged? Because blockade of either NOX or mitochondrial source of ROS completely 
inhibited ET-1-inudced ROS generation as well as the activation of ICl,swell, the two ROS 
generating systems must work in serial rather than in parallel. We also showed that the 
activation ICl,swell induced by osmotic swelling, which was shown to be dependent on 
NOX, was blocked by rotenone (data not shown), and stimulation of ICl,swell by ACh, 
which was ascribed to mitochondrial ROS, was inhibited by NOX inhibitor apocynin 
(data not shown). Taken together, these data indicates serial crosstalk between NOX and 
mitochondria in the regulation of ICl,swell. 
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 Both NOX and mitochondrial ROS production can be stimulated by ROS. ROS 
stimulates the signaling pathway that leads to the activation of NOX (Cai, 2005), and 
local release of ROS may trigger self-sustained oscillations of  mitochondrial membrane 
potential and ROS production that propagate from one mitochondrion to another 
throughout myocytes, which is referred to as mitochondrial ROS-induced ROS release 
(RIRR) (Zorov et al., 2000; Aon et al., 2003; Aon et al., 2008). Therefore, there are two 
possibilities for the direction of the crosstalk: mitochondria is upstream from NOX and 
induces ROS production by NOX. Alternatively, NOX is upstream from mitochondria 
and enhances mitochondrial ROS production.  
 Antimyosin A induces O2− production from the Qo site of Complex III by binding 
to a distal site near Qi and preventing e– transfer from cytochrome bH (Chen et al., 2003; 
Turrens, 2003). Diazoxide elicits mitochondrial ROS production by opening mitoKATP 
channels (Pain et al ., 2000; Oldenburg et al. , 2003). Preliminary data shows that two 
stimulators of mitochondrial ROS, antimycin A and diazoxide, induce ICl,swell in 
ventricular myocytes that is inhibited by 5-HD, a blocker of the MitoKATP channel 
(Browe & Baumgarten, 2007).  
 In the present study, we showed that the activation of ICl,swell in response to 
antimycin A and diazoxide was insensitive to the selective NOX inhibitor apocynin and 
the fusion peptide inhibitor gp91ds-tat.  These results rule out the possibility that NADPH 
oxidase is downstream from mitochondrial ROS production. Rather, the data suggest that 
mitochondrial ROS is downstream from NOX in the signaling pathway regulating ICl,swell. 
We propose that low levels of ROS produced by NOX might trigger the production of a 
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greater amount of ROS by mitochondria, which is responsible for the activation of  
ICl,swell. Subsarcolemmal mitochondria are well-positioned for this role (Palmer et al. , 
1977); they are located adjacent to both NOX on surface membrane and to ICl,swell. 
 The underlying mechanism by which NOX interacts with mitochondria has not 
been illuminated. One possibility is that ROS produced by NOX directly modify and 
open mitoKATP channels by oxidizing SH groups within the channel (Zhang et al., 2001). 
Another possibility is mitochondrial RIRR, which is generated by circuits requiring 
mitochondrial membrane channels including the mitochondrial permeability transition 
(MPT) pore and the inner membrane anion channel (IMAC) (Zorov et al. , 2006). The 
role of MPT and IMAC was not examined in the current study.  
5.9. Osmotic Shrinkage-Induced Signaling is Proximal to Mitochondrial ROS in the  
Regulation of ICl,swell. 
 The signaling induced by osmotic shrinkage is not been fully understood. 
Previous studies indicated that integrins (Sheikh-Hamad et al. , 1997; Sheikh-Hamad et 
al., 2000; Pedersen et al., 2001; Haussinger et al., 2006), FAK (Lunn & Rozengurt, 2004; 
Lunn et al. , 2007), Src family kinases (Lunn & Rozengurt, 2004; Reinehr et al., 2004), 
Rho family GTPases (Lunn & Rozengurt, 2004), and EGFR kinase (Rosette & Karin, 
1996; Cheng et al. , 2002; Reinehr et al. , 2003) are involved in shrinkage-activated 
responses in non-cardiac cells. Osmotic shrinkage was shown to inhibit EGF receptor-
mediated signaling in kidney cells (Copp et al. , 2005) and suppress the PI-3K-Akt and 
MEK1/2-ERK1/2 pathways in  NIH3T3-fibroblasts (Nielsen et al., 2008).   
85 
 
 
 Osmotic shrinkage with hyperosmotic bathing media inhibited the activation of 
ICl,swell induced by β1 integrin stretch and EGF (Browe & Baumgarten, 2006) but failed to 
inhibit H2O2-induced ICl,swell, suggesting that H2O2 acts at sites distal to those regulated by 
osmotic shrinkage (Ren et al., 2008). In the present study, we showed that the activation 
of ICl,swell in response to antimycin A, which stimulates mitochondrial ROS directly, also 
was insensitive to osmotic shrinkage. These data indicates that mitochondrial ROS is 
distal from the sites that are regulated by osmotic shrinkage. Based on previous studies, 
we propose that osmotic shrinkage might regulate ICl,swell at site(s) between EGFR kinase 
and mitochondrial ROS. 
5.10. ERK-Dependent and ERK-Independent Activation of ICl,swell by ET-1, EGF, and 
H2O2 
ERK signaling plays a pivotal  role in the cardiac hypertrophy and cardiomyocyte 
survival (Heineke & Molkentin, 2006; Muslin, 2008). ERK is activated by mechanical 
stretch (Caldiz et al., 2007; Lal et al., 2007), AngII (Fischer et al., 1998; Ruf et al., 2002; 
Booz et al., 2003), EGF (Kodama et al., 2002; Duquesnes et al., 2009), ET-1 
(Bogoyevitch et al., 1993; Bogoyevitch et al., 1994), and H2O2 (Aikawa et al., 1997; 
Fukuzawa et al., 2002; Daou & Srivastava, 2004; Mehdi et al., 2005). The present and 
previous studies demonstrate that all of these signaling effectors are upstream regulators 
of ICl,swell (Du & Sorota, 2000; Browe & Baumgarten, 2003; Browe & Baumgarten, 2004; 
Browe & Baumgarten, 2006).  
 ERK1/2 blockade was shown to inhibit the persistent activation of ICl,swell in the 
failing heart (Clemo & Baumgarten, 1999) and the potentiation of ICl,swell by ET-2 (Du & 
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Sorota, 2000).  In the current study we showed that EGF-induced ICl,swell was fully 
inhibited by blockade of ERK1/2 with PD98059 or ERK1 with U0216. However, both 
PD98059 and U0216 partially inhibited ET-1-induced ICl,swell. These data suggest that 
EGF activated ICl,swell via an ERK-dependent pathway and  there are both ERK-dependent 
and independent pathway involved in ET-1 signaling, but the pathway is likely to be 
complex. Although ERK is known to be activated by H2O2, H2O2 also appears to be distal 
from ERK signaling in the regulation of ICl,swell, as ERK1/2 inhibitor PD98059 had no 
effect on H2O2 elicited ICl,swell. Other aspects of the complicated ERK1/2 signaling 
cascade were not explored.   
5.11. ETA Receptors Mediate the Activation of ICl,swell by AngII and Osmotic Swelling 
 Although the primary goal of the present study was to understand regulation of 
ICl,swell by ET-1, we also established the relationship of ET-1 to the effects of osmotic 
swelling and AngII. Both osmotic swelling and β1 integrin stretch activate ICl,swell via 
AngII AT1 signaling that ultimately leads to ROS production (Browe & Baumgarten, 
2004; Ren et al., 2008). AngII induces synthesis and release of ET-1 in cardiomyocytes, 
and there is evidence that ET-1 mediates AngII-induced ROS production as well as other 
ROS dependent effects (Ito et al., 1993; Cingolani et al., 2006; Villa-Abrille et al., 2006). 
We found that the activation of ICl,swell induced by AngII and osmotic swelling was 
abolished by ETA receptor blockade wheras AT1R blocker had no effect on activation of 
ICl,swell  induced by ET-1,  suggesting that ET-1 ETA signaling is downstream from AngII 
and osmotic swelling. We did not measure ET-1 release in response to AngII and osmotic 
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swelling, but it is likely that the atrial myocyte under study was exposed to ET-1 released 
by the same myocyte as well as by other myocytes in the chamber.   
 We postulate that the acute effect of AngII and osmotic swelling is mediated by 
release to preformed ET-1 rather than the induction of ET-1 transcription and synthesis.  
Prolonged exposures to AngII or hyposmotic bath solution can not be accomplished in 
the present patch clamp studies that used each myocyte as its own control.  On the other 
hand, it is likely that the upregulation of the ET-1 transcription is involved in the 
persistent activation of ICl,swell under the situations that RAAS is chronically overactive, 
such as congestive heart failure and atrial fibrillation.   
 The signaling by which AngII induces transcription and release of ET-1 in 
cardiomyocytes was not understood. ROS and ERK1/2 are involved in AngII-induced 
ET-1 transcription in multiple non-cardiac cell types, including vascular smooth muscle 
cells (Hong et al., 2004), endothelial cells (Hsu et al., 2004), and fibroblasts (Cheng et 
al., 2003; An et al., 2007). ET-1 was shown to directly modulates its own expression in 
human endothelial cells and mesangial cells (Iwasaki et al., 1995; Evans et al., 2003). It 
is plausible that ET-1-induced ROS production and activation of ERK feed forward to 
enhance its expression and contribute to the profound and long-lasting effects of ET-1. 
5.12. Proposed Model for the Regulation of ICl,swell by ET-1 
 A scheme accounting for both our present and previous studies is shown in Fig. 
24.  ET-1-induced ICl,swell was abrogated by selective blockade of ETA receptor, EGFR 
kinase and PI-3K, suggesting that ET-1 activates ICl,swell via a signaling cascade involving 
ETA receptor, EGFR kinase and PI-3K. PI-3K is downstream from EGFR kinase because 
inhibition of PI-3K suppressed EGF-induced ICl,swell (Browe & Baumgarten, 2006).  PI-
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Figure. 24.  Simplified schematic diagram of ET-1 signaling responsible for the. 
activation of ICl,swell.  Dark Blue, signaling pathways; Green, stimpulates ROS and 
ICl,swell; Red, blocks ROS and ICl,swell; Arrow, acts by stimulating pathway; T, acts by 
inhibiting pathway; X, fails to block pathway; Dashed Line, one or more steps unknown.  
Results with ERK blockers are omitted because the signaling pathway remains unclear.  
Effects of osmotic shrinkage are also omitted.   
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3K has been implicated in the assembly and activation of NOX. The O2− produced by 
NOX undergoes rapidly dismutation to H2O2, which has been shown to be a distal 
downstream mediator of the activation of ICl,swell by β1 integrin stretch and osmotic 
swelling (Browe & Baumgarten, 2004; Ren et al., 2008). Consistent with previous 
findings, ET-induced ICl,swell was abolished by membrane-permeant glutathione 
peroxidase mimetic ebselen and selective NOX inhibitor apocynin. Moreover, 
pretreatment of specific NOX inhibitor gp91ds-tat abolished ET-1-induced ROS 
production. The low level of ROS produced by NOX might induce a larger ROS 
production by mitochondria, and this amplification of ROS production is likely to be 
responsible for the activation of ICl,swell. In agreement with this idea, Complex I inhibitor 
rotenone fully blocked the ET-1-induced ROS production as well as the activation of 
ICl,swell. Mitochondrial ROS is downstream from NOX because the ICl,swell elicited by 
mitochondrial ROS stimulators antimycin A and diazoxide is insensitive to NOX 
inhibitors.  
5.13. ICl,swell is Regulated by ROS and ET-1 in HL-1 Cells 
 HL-1 atrial myocytes are a recently developed model for studying cardiac 
myocytes. This preparation is characterized as an immortalized mouse atrial muscle cell 
line that retains certain morphological, biochemical, and electrophysiological properties 
of adult cardiomyocytes (Claycomb et al., 1998). HL-1 cells offer several advantages 
over acutely isolated adult myocytes, including the ability to apply a variety of molecular 
methods that require the culture of the targeted cells. Cl currents have not previously 
been studied in HL-1 atrial myocytes, and the present experiments were undertaken to 
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examine whether ICl,swell is present in these cultured cells and whether its regulation was 
similar to that in adult cells.  
 ICl,swell in HL-1 cells was identified by the sensitivity to DCPIB and outward 
rectification in  both physiological and symmetrical Cl. ICl,swell was present at a much 
higher current density than typically observed in adult myocytes.  Moreover, using the 
same approaches employed in adult myocytes, we demonstrated that activation of ICl,swell 
was controlled by ET1-1 and both NOX  and mitochondrial ROS. Only one difference 
was noted.  The NADPH oxidase inhibitor apocynin was ineffective in HL-1 cells, 
although ICl,swell still was fully suppressed by gp91ds-tat, another selective NADPH 
oxidase inhibitor. Apocynin is a prodrug that must be converted to its active form, usually 
by peroxidases (Heumuller et al., 2008).  This raises the possibility that insufficient 
peroxidases are present in HL-1 cells to effectively convert apocynin to its active form. 
 HL-1 myocytes also were very useful for flow cytometry. Acutely isolated 
preparations of adult cardiac myocytes contain damaged and dead cells that produce 
ROS. This creates a serious technical problem in measuring ROS production by flow 
cytometry. In contrast, HL-1 cell preparations contain far fewer damaged or dead cells, 
and the background ROS production and the background activation of ICl,swell were much 
lower. The present studies suggest that HL-1 cells are likely to be useful for future studies 
of ICl,swell as well as ROS generation by other stimuli.  
5.14. Implication of the Present Study 
Excessive levels of ET-1 have been identified in multiple cardiovascular diseases, 
including congestive heart failure(Moe et al., 2003), atrial fibrillation (Tuinenburg et al., 
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1998; Brundel et al., 2001; Masson et al., 2006), essential hypertension(Touyz & 
Schiffrin, 2003), salt sensitive hypertension (Feldstein & Romero, 2007), pulmonary 
hypertension (Jasmin et al., 2003), pre-eclampsia (Florijn et al., 1991), atherosclerosis 
(Bousette & Giaid, 2003), acute myocardial infarction (Cernacek et al., 2003), 
ischemia/reperfusion injury (Pernow & Wang, 1997), myocarditis (Ono et al., 1999), 
sepsis induced myocardial dysfunction (Chopra & Sharma, 2007), and diabetic 
cardiovascular complications (Chakrabarti et al., 2002). As shown in the present study, 
ET-1 activates ICl,swell under isosmotic conditions, which implies that activation of  ICl,swell 
might be involved in the pathogenesis of cardiovascular diseases in which ET-1 is over-
produced. Recent studies showed that ICl,swell  is involved in the apoptosis  of 
cardiomyocytes and hippocampal neurons induced by ischaemia–reperfusion (Wang et 
al., 2005; Inoue et al., 2007). Besides the role in apoptosis, ICl,swell also will affect cardiac 
electrical activity and may potentially participate in arrhythmogenesis. The APD 
shortening effect of ICl,swell might protect against EAD and torsade de pointes. On the 
other hand, it favors reentrant arrhythmias such as atrial fibrillation. The pathophysiolog- 
-ical role of ICl,swell in atrial fibrillation and other cardiovascular diseases still awaits to be 
established by in vivo studies.    
The finding that mitochondrial ROS is responsible for the activation of  ICl,swell  
indicates that this current also will be turned on in a variety of situations that 
mitochondrial ROS production is activated, including heart failure(Ide et al., 1999; Ide et 
al., 2000) , myocardial infarction (Ide et al., 2001), and ischemia/reperfusion (Ambrosio 
et al., 1993). The crosstalk between NOX and mitochondria established by this study 
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might be a general scheme that is implicated in multiple signaling events including 
regulation of ICl,swell by other stimuli than ET-1, the inotropic response, and 
ischemia/reperfusion injury.  
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